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ABSTRACT	
 
 
Expression	of	human	leukocyte	antigen	(HLA)	molecules	is	essential	for	anti-
tumour	immune	responses.	Interferon	gamma	(IFN-γ)	up-regulates	HLA	and,	
paradoxically,	programmed	cell	death	ligand-1	(PD-L1),	which	inhibits	immune	
activation.	The	mitogen-activated	protein	kinase	pathway	(MAPK),	overactivated	in	
triple	negative	breast	cancer	(TNBC),	is	implicated	in	HLA	and	PD-L1	expression.	We	
hypothesized	that	its	inhibition	may	modulate	HLA	and	PD-L1	expression	in	TNBC.	
	
Human	TNBC	and	non-TNBC	cell	lines	were	treated	with	various	MEK	inhibitors	
(MEKi)	in	the	presence/absence	of	IFN-γ.	Flow	cytometry,	immunofluorescence	and	
Western	blotting	were	used	to	assess	MEKi	mediated	changes	in	constitutive	and	
inducible	HLA	and	PD-L1	expression.	
	
U0126	antagonized	cell	surface	HLA	expression,	but	not	total	HLA	protein,	while	
the	clinically	relevant	MEKi(s),	Trametinib	and	Selumetinib,	generally	augmented	
constitutive	and	inducible	cell	surface	HLA	class	I.		All	MEKi	(s)	reduced	PD-L1	expression.	
These	results	have	important	implications	for	MEKi	in	targeting	immunotherapy	for	
TNBC.	
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Chapter	1:	Introduction	
	
1.	Breast	Cancer		
Breast	cancer	is	the	most	common	malignancy	in	women	worldwide,	and	despite	
significant	advancements	in	treatment,	the	death	toll	for	Canadian	women	before	this	
year	ends	will	be	approximately	50001.	Despite	better	health	care,	earlier	detection	and	
treatments,	breast	cancer	is	the	second	leading	cause	of	cancer-related	death	in	
Canadian	women1,2.	This	is	in	large	part	due	to	the	vast	differences	between	the	subsets	
of	breast	cancer.		
Breast	cancer	can	be	sub-divided	into	three	main	groups:		
1.	Luminal	A,	consists	of	tumours	that	are	ER-α+,	can	be	PR+/-	and	HER-2	negative,		
2.	Luminal	B,	consists	of	tumours	that	are	ER-α+,	PR+	and	HER-2+	and,		
3.	Triple	negative	(TN)/basal	like,	which	are	breast	tumours	that	are	ER-α-,	PR-,	
and	HER2-.		
	
Luminal	A	breast	tumours	tend	to	have	the	best	prognosis,	whereas	the	most	
aggressive	subset	is	triple	negative	breast	cancer	(TNBC),	aptly	named	due	to	its	absence	
of	the	ER,	PR,	and	lack	of	HER2	on	the	tumour	surface3,4.	This	cancer	tends	to	affect	
younger	women;	has	a	worse	prognosis	and	is	more	prominent	in	African	American	
female	populations5.	Because	of	the	lack	of	targets	for	conventional	therapies,	non-
specific	treatments	such	as	radiation	and	the	only	systemic	therapy	currently	available	is	
chemotherapy6	and	additional	treatments	are	limited.	NAC	is	gaining	in	popularity	and	
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has	a	success	rate	of	pCR	in	30%	of	TNBC	patients7.	However,	in	the	remaining	70%,	
there	exists	some	potential	micro-metastases	and	recurrence7,8.	TNBC(s)	account	for	
approximately	10-17%	of	all	breast	cancers.	Given	its	poor	prognosis	and	difficulty	to	
treat,	TNBC	remains	an	important	research	area	with	a	focus	on	finding	new	treatment	
options.		
There	are	ways	to	predict	a	patient’s	response	to	treatment,	including	the	TMN	
staging	classification	system,	which	takes	into	account	the	size	of	the	initial	tumor,	the	
nearby	affected	lymph	nodes	and	if	the	tumour	has	metastasized9,	as	well	as	the	
expression	of	receptors	on	the	tumour	surface.	Additionally,	the	number,	location,	and	
types	of	TILs	can	also	be	indicative	of	a	patient’s	response10.	TILs	are	immune	cells	that,	
when	activated,	can	proliferate	and	destroy	foreign	or	harmful	material	within	the	body	
(including	tumours)	however	in	order	to	activate	these	cells,	tumour	antigens	must	be	
presented	to	them.	This	so-called	“presentation”	is	achieved	via	MHC	or	HLA;	in	
humans.11,12	
Among	new	cancer	treatment	options,	immunotherapy	has	emerged	as	a	viable	
option	for	those	who	are	not	eligible	for,	or	resistant	to,	usual	treatments.	Ever	since	it	
was	discovered	in	1957	that	tumour	cells	could	potentially	evoke	an	immune	response,	
research	has	been	intent	upon	finding	ways	to	make	cancer	more	recognizable	to	our	
immune	systems13.	
1.2	Major	Histocompatibility	Complex	
	
	 3	
1.2.1	Overview	
MHC,	or	HLA	in	humans,	is	located	on	chromosome	614.	There	are	three	HLA	
regions:	class	I,	class	II	and	class	III.	HLA	class	I	molecules	are	expressed	on	the	cell	
surface	of	nearly	all	nucleated	cells	including	tumour	cells,	and	their	function	is	to	
present	peptides	of	approximately	8-10	amino	acids	in	length	that	has	been	digested	
inside	the	cell	to	CD8+	T-cells,	whereas	HLA	class	II	present	peptides	to	CD4+	T	cells,	also	
called	helper	T-cells15.	Activation	of	both	CD4	and	CD8+	T	cells	into	an	effector	cell	is	
achieved	through	the	recognition	of	two	signals;	the	first	signal	is	the	interaction	of	the	
HLA-loaded	molecules	with	the	TCRs	and	associated	proteins.	The	second	signal	needed	
is	the	interaction	of	the	co-stimulatory	molecules	such	as	the	B7	proteins	(CD80	and	
CD86)	on	the	APC	with	CD28	present	on	the	T	cell.	CD4+	T	cells	are	also	important	in	
helping	CD8+	T	cell	activation	as	well.	CD4+	cells	can	first	interact	with	APCs	such	as	DCs	
that	have	taken	up	tumour	antigen	and	then	migrated	to	the	lymph	nodes	to	display	this	
antigenic	peptide	to	naïve	T	cells.	If	recognized,	then	the	T	cell	can	differentiate	into	
effector	T	cells.	If	these	activated	cells	are	CD8+	cytolytic	T	cells,	they	can	initiate	tumour	
destruction16.	The	HLA	class	I	glycoproteins	form	heterodimers	with	another	molecule	
that	is	coded	for	by	a	separate	gene,	the	β2m17	(Figure	1.1).	
Tumour	antigens	can	also	be	presented	on	HLA	class	II	molecules,	which	normally	
are	only	present	on	APCs,	such	as	B	cells,	Dendritic	cells	and	macrophages18.	HLA	class	II	
consists	of	the	heterodimeric	molecules	HLA-DR,	HLA-DQ,	and	HLA-DP	that	consist	of	
two	distal	and	two	proximal	α1	and	β1	domains	that	are	coded	for	by	exon	2	and	3	of	
the	alpha	and	beta	chain	genes,	whereas	HLA-DR	is	encoded	by	the	DRA	and	DRB		
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Figure	1.1:Human	leukocyte	antigen	class	I	molecule	structure:	The	HLA	class	I	
glycoproteins	(α1,	α2,	&	α3)	combine	with	β2m,	forming	a	heterodimer.	HLA	class	I	is	
anchored	in	the	plasma	membrane	via	transmembrane	domains	(TM)	and	a	cytoplasmic	
tail.	Adapted	from	(15).	
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genes11.	The	peptide	binding	groove	is	comprised	of	two	alpha	helices	above	a	beta-
pleated	sheet	and	is	open-ended,	unlike	the	closed-ended	groove	in	class	I,	in	order	to	
bind	peptides	that	are	12-24	amino	acids	long.	HLA	class	II	molecules	present	peptides	
derived	from	endocytosed	proteins	to	CD4+	T	cells,	which	upon	activation	differentiate	
into	one	of	several	subsets,	depending	in	part	on	the	cytokine	milieu18	(Figure	1.2).	
Several	different	CD4	T-cell	subsets	have	been	identified	in	the	tumour	
microenvironment	including	TH1	(producing	IFN-γ),	TH2	(IL-4)	and	regulatory	T-cells19.		
The	expression	of	HLA	class	II	can	be	induced	on	other	cell	types	through	
stimulation	of	certain	cytokines,	including,	but	not	limited	to,	IFN-γ.	IFN-γ	also	further	
increases	HLA	class	I	expression.	Higher	expression	of	these	molecules,	especially	HLA	
class	I,	has	been	associated	with	positive	outcomes	for	the	patient	in	some	cancer	
types8.		
	
1.2.2	Endogenous	HLA	class	I	Pathway	
	
Classical	HLA	class	I	molecules	are	assembled	in	the	endoplasmic	reticulum	(ER),	
whereas	the	proteins	that	are	recognized	by	the	cell	as	foreign	are	degraded	into	
peptides	by	the	proteasome,	an	ATP-dependent	protease,	in	the	cytosol17.	The	peptides	
are	then	translocated	to	the	ER	by	the	TAP	proteins.	ER	chaperones,	calnexin	and	
calrecticulin	as	well	as	tapasin	facilitate	the	assembly	of	the	β2m	with	the	heterodimers	
to	make	the	complete	HLA	molecule.	Once	the	peptide	is	bound	into	the	peptide-	
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Figure	1.2:	Human	leukocyte	antigen	class	II	molecule	structure.	The	HLA	class	II	
molecule	is	comprised	of	two	glycoprotein	transmembrane	chains,	an	α	and	a	β	chain.	
HLA	class	II	molecules	are	anchored	in	the	plasma	membrane	via	the	TM	and	
cytoplasmic	tails.	Adapted	from	(12)		
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binding	groove,	the	molecule	begins	transport	to	the	cell	surface.	Without	peptide	
binding,	the	proteasome	subsequently	degrades	the	HLA	molecule17	(Figure	1.3).	
	
1.2.3	Exogenous	HLA	class	II	Pathway	
	
HLA	class	II	molecules	are	also	assembled	in	the	ER	along	with	the	Ii12.	The	Ii	has	
multiple	functions:	It	serves	as	a	co-chaperone	in	the	assembly	of	HLA	class	II,	ensuring	
proper	folding	and	stability,	also,	the	Ii	binds	to	the	peptide-binding	groove	of	class	II	
and	acts	as	a	peptide	editor;	exchanging	itself	out	for	other	peptides	of	the	correct	
size20,21.	The	Ii	chain	trimer	acts	to	block	the	peptide-binding	cleft	in	the	HLA	class	II	
molecule,	the	two	trimers	(nonamer)	then	migrate	from	the	ER	to	the	Golgi	apparatus	
and	the	endocytic	compartment	where	the	lysosomes	then	fuse	with	a	late-endosome-
like	compartment	containing	large	amounts	of	HLA	class	II	molecules,	called	MIIC.	
Cathepsin	S	subsequently	degrades	the	Ii,	leaving	a	small	peptide	called	CLIP22.	This	
peptide	is	then	exchanged	for	a	higher	affinity	peptide	as	the	fully	assembled	class	II	
molecule	makes	its	way	to	the	surface	of	the	cell23	(Figure	1.4).	
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Figure	1.3:	Endogenous	human	leukocyte	antigen	class	I	pathway.	
HLA	class	I	proteins	are	synthesized	in	the	endoplasmic	reticulum	(ER)	and	antigenic	
proteins	are	degraded	by	the	proteasome	in	the	cytosol.	TAP	molecules	translocate	the	
peptides	to	the	ER.	ER	chaperones,	calnexin	and	calrecticulin	as	well	as	tapasin	facilitate	
the	assembly	of	the	β2m	with	the	heterodimers	to	make	the	complete	HLA	molecule.	
Once	the	peptide	is	stably	bound	into	the	peptide-binding	groove,	the	molecule	begins	
transport	to	the	cell	surface.	Adapted	from	(17).	
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Figure	1.4:	Exogenous	human	leukocyte	antigen	class	II	pathway.	
HLA	class	II	heterodimers	are	synthesized	in	the	endoplasmic	reticulum	along	with	the	Ii,	
which	acts	as	a	peptide	editor	that	sits	in	the	peptide	binding	groove.	The	HLA	class	II	
molecule	and	the	Ii	combine	to	form	the	(αβ)3Ii3	complex,	which	then	moves	into	the	
MIIC.	Cathepsin	S	degrades	the	Ii,	leaving	behind	the	CLIP	fragment.	HLA-DM,	associated	
with	HLA-DO,	acts	to	switch	out	the	CLIP	fragment	in	exchange	for	a	high	affinity	
peptide.	HLA-DM	and	DO	dissociates	from	the	HLA	complex,	and	the	HLA	complex,	
loaded	with	the	peptide	is	transported	to	the	cell	surface.	Adapted	from	(20).	
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1.2.4	Class	II	Transactivator	and	Function	
The	CIITA	regulates	expression	of	the	class	II	molecule.	CIITA	is	a	non-DNA	
binding	protein	that	acts	as	a	transcriptional	integrator.	Its	expression	directly	correlates	
with	the	expression	of	class	II	genes24.	A	large,	regulatory	protein	drives	the	
transcriptional	activity	of	CIITA.	This	gene	contains	four	promoter	regions:	pI,	pII,	pIII,	&	
pIV.	With	the	exception	of	pII,	with	its	function	unknown,	pI,	pIII	and	pIV	are	all	highly	
conserved	between	mice	and	humans	and	their	functions	are	as	follows:	pI	is	a	myeloid-
specific	cell	promoter	and	drives	CIITA	in	macrophages	that	are	activated	by	IFN-γ	as	
well	as	DCs.	pIII	is	lymphoid	cell-specific	and	is	responsible	for	driving	CIITA	in	B-cells,	
DCs	and	activated	T-cells.	pIV	drives	CIITA	expression	in	non-bone	marrow	derived	cells	
through	IFN-γ	stimulation24	(Figure	1.5).	
	
1.2.5	Expression	of	Major	Histocompatibility	Complexes(s)	I	&	II	in	Breast	Cancer	
	
	 Expression	of	HLA	class	I	is	required	to	activate	an	immune	response	by	CD8+	T-
cells,	and	in	cases	of	cancer,	the	activation	of	anti-tumour	CTLs	is	dependent	upon	the	
recognition	of	epitopes	that	are	presented	on	the	HLA	class	I	molecule	on	the	tumour	
cell25.	Therefore,	the	loss	of	these	surface	molecules	can	lead	to	reduced	activation	of	
CTLs	and	reduced	killing	of	tumour	cells	leading	to	increased	malignancy.	The	down-
regulation	of	HLA	class	I	is	believed	to	be	one	of	the	main	mechanisms	by	which	tumours	
evade	the	immune	system	and	the	loss	of	such	molecules	has	been	shown	to	increase	
tumour	aggressiveness	and	invasiveness10,26.	Specifically,	in	breast	cancer,		
approximately	two	thirds	of	tumours	have	shown	HLA	class	I	loss27,28.	
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Figure	1.5:	Regulation	of	human	leukocyte	antigen	class	II	expression.		
The	regulation	of	HLA	class	II	is	performed	at	the	transcriptional	level	by	binding	
regulatory	factor	X	(RFX),	CREB,	and	the	NF-Y	for	the	S,X,Y	module	that	is	in	the	
promoter	of	HLA	class	II	genes.	This	allows	the	CIITA	to	bind	and	recruit	transcription	
machinery.	Adapted	from	(21).	
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The	consequences	of	such	loss	is	significant	for	nodal	metastasis,	lymphatic	invasion	and	
venous	invasion27.	The	study	by	Kaneko	and	colleages	(2011)	also	showed	that	patients	
with	HLA	class	I-positive	tumours	have	significantly	longer	disease-free	survival	(DFS)	
than	those	with	HLA	class	I-deficient	tumours,	emphasizing	the	importance	of	having	
available	HLA	class	I	molecules	on	the	tumour	surface	to	present	antigenic	peptides	to	
surrounding	lymphocytes.	Although	there	are	many	HLA	aberrations	across	the	various	
cancers,	the	loss	of	HLA	class	I	seems	to	have	universally	negative	clinical	
implications10,26.	
As	previously	mentioned,	HLA	class	II	molecules	are	only	constitutively	expressed	
on	APCs;	regular	breast	epithelial	cells	do	not	express	HLA	class	II	except	during	
lactation29.	However,	patients	with	breast	cancer	express	HLA	class	II	in	approximately	
50%	of	cases,	begging	the	question	of	the	clinical	implication(s)	of	HLA	class	II	expression	
on	breast	tumour	cells19.	HLA-DR	is	the	most	commonly	expressed	HLA	class	II	molecule	
on	breast	tumours,	followed	by	HLA-DP	and	DQ30.	HLA	class	II	can	be	induced	through	
stimulation	of	certain	cytokines,	most	notably	IFN-γ,	as	well	as	interleukin	alpha	(IL-α),	
interleukin	beta	(IL-β),	tumour	necrosis	factor	alpha	(TNF-α),	interleukin-4	(IL-4)	and	
estradiol	(E2)25.		
There	is	yet	no	consensus	regarding	the	prognostic	implication	of	expressing	HLA	
class	II	on	breast	cancer	cells,	as	the	results	have	been	varied	and	contradictory.	In	some	
studies,	HLA	class	II	up-regulation	through	stimulation	of	the	cytokine	milieu	in	the	
tumour	environment	has	been	shown	to	induce	an	anti-tumour	T-cell	response	
suggesting	a	benefit	of	HLA	class	II	expression31–33.	However,	this	association	is	not	clear;	
	 18	
with	some	studies	showing	that	HLA-DR	expression	is	associated	with	a	favorable	
prognosis,	and	good	differentiation34,	whereas	others	have	found	no	relationship	
between	the	two35,36.		
Increased	HLA-DR	expression	has	been	observed	in	ERα-	tumours,	suggesting	
that	ER	has	a	role	in	down-regulating	HLA-DR37.	The	relationship	between	HLA	class	II	
and	prognosis	may	not	be	unambiguous,	as	it	has	been	shown	that	outcomes	differ	
depending	on	the	co-chaperones	present,	including	HLA-DM	and	the	Ii19.	In	a	study	by	
Oldford	and	colleagues	(2006),	it	was	shown	that	discordant	expression	of	these	may	
negatively	impact	peptide	presentation19.	
	
1.3	Interferons		
	
	 Interferons	are	cytokines	that	play	various	roles	in	the	immune	system.	They	can	
interfere	with	virus	replication,	cause	inflammation	and	are	secreted	by	some	of	the	
first-line	defenders	of	the	immune	system	itself:	NK	cells	and	NKT	cells.	There	are	three	
classes	of	interferons:	class	I	has	IFN-α	and	IFN-β,	class	II	consists	of	IFN-γ,	and	class	III	
contains	IFN-λ38.	The	remainder	of	this	introduction	will	focus	on	the	class	II	Interferon,	
IFN-γ,	and	its	classical	signal-transduction	pathway	(Figure	1.6).		
	
1.3.1	IFN-γ	Pathway	and	Function	
	
When	released,	IFN-γ	binds	to	its	cell-surface	IFNGR.	This	receptor	consists	of	
two	IFNGR1,	and	two	IFNGR2	chains	that	are	responsible	for	ligand	binding	and	signal	
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Figure	1.6:	Interferon	gamma	signaling	pathway.		
IFN-γ	binds	to	the	surface	interferon	gamma	receptor(s)	1	and	2	and	the	signal	is	sent	
down	to	activate	the	JAK	I	&	2,	leading	to	the	phosphorylation	of	STAT-1.	The	resulting	
dimer	then	translocates	to	the	nucleus	and	then	activates	its	target	promoters.	Adapted	
from	(21).	
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transduction,	respectively.	Once	this	binding	occurs,	the	signal	is	sent	down	through	the	
receptor	to	activate	the	receptor-associated	protein	tyrosine	kinases	JAK1	&	JAK2.	This	
leads	to	the	phosphorylation	of	Signal	Transducer	and	Activators	of	Transcription-1	
(STAT-1),	which	then	dimerizes	thereby	allowing	the	homodimer	to	translocate	to	the	
nucleus	and	activate	its	target	promoters	including	pIV	and	Interferon	Regulator	Factor-
1	(IRF-1)24.	STAT-1	homodimer	activates	gene	transcription	by	binding	to	the	GAS	site	
located	in	the	promoter	region	of	genes.	This	whole	process	of	early	gene	transcription	
takes	approximately	15-30	minutes38.		
IFN-γ	signaling	can	also	occur	independently	from	JAK/STAT-1	in	the	non-classical	
pathway	and	it	has	been	shown	that	30%	of	genes	stimulated	by	IFN-γ	signaling	occur	in	
the	absence	of	STAT-139.	There	are	other	signaling	pathways	that	work	parallel	to	
JAK/STAT-1	signaling	including	the	PI3-K/AKT,	PKC	and	the	MAPK	pathway,	all	of	which	
have	been	shown	to	phosphorylate	STAT-139.	In	addition	to	the	activation	of	the	MAPK	
pathway,	IFN-γ	can	also	cause	the	up-regulation	of	certain	cell-surface	molecules	such	as	
HLA-DR	and	PD-L140.	
	
1.4	Programmed	Cell	Death	Ligand-1	Structure	and	Function	
	
	 PD	-L1	or	B7-H1	is	a	cell-surface	protein	belonging	to	the	B7	family41	(Figure	1.7).	
The	ligand	is	expressed	on	APCs	and,	like	HLA	class	II	molecules,	can	be	induced	by	
cytokines	such	as	IFN-γ40.	PD-L1	interacts	with	the	PD-1	receptor	expressed	on	B-cells,	
natural	killer	cells,	and	activated	CD8+	and	CD4+	T-lymphocytes	causing	inhibition	
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and/or	apoptosis2.Due	to	its	inhibitive	nature,	the	PD-1/PD-L1	interaction	is	a	critical	
component	of	immune	regulation.	Because	of	their	roles	in	immunoregulation,	the	
presence	of	PD-L1	on	tumour	cells	has	been	suggested	to	help	protect	the	cells	from	
immune	surveillance42.		
	 	
1.4.1	Programmed	Cell	Death	Ligand-1	expression	and	MAPK	pathway	
	
Because	IFN-γ	is	the	best-known	regulator	of	PD-L1,	pathways	that	respond	to	
IFN-γ	stimulation,	such	as	the	JAK/STAT	pathway,	PI3K	and	MAPK	pathways	have	been	
shown	to	induce	IFN-γ-mediated	PD-L1	expression	on	tumour	cells43.	This	was	
demonstrated	in	a	study	by	Cheng	and	colleagues	(2007)		that	treatment	of	multiple	
myeloma	plasma	cells	with	the	pan	MEK	inhibitor	U0126	and	IFN-γ	resulted	in	
dramatically	decreased	PD-L1	expression,	whereas	treatment	with	PI3K	inhibitor	
LY294002,	P38	inhibitor	SB203580,	and	NFκB	inhibitor	SN50	had	no	such	effect44.	The	
importance	of	MAPK	in	PD-L1	was	also	demonstrated	in	a	study	by	Falchook	et	al	(2012)	
in	which	blocking	MEK	inhibited	PD-L1	transcription	in	AML45.	The	modulation	of	PD-L1	
by	MAPK	has	been	observed	in	a	number	of	different	cancers	including	anaplastic	large	
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Figure	1.7:	Interaction	of	PD-1	on	T-cell	with	Programmed	Cell	Death	Ligand-1	expressed	
on	tumour	cell.	
PD-L1	(B7-H1)	expressed	on	tumour	cell	surface	interacts	with	the	corresponding	PD-1	
molecule	on	the	CD8+	or	CD4+	T-cell.	Interaction	leads	to	signal	proprogation,	which	
causes	phosphorylation	of	ITIM	and	ITSM.	ITSM	interacts	with	SHP-2,	which	then	
becomes	dephosphoylated,	leading	to	phosphorylation	of	proximal	signaling	kinases.	
This	interaction	leads	to	inhibition	of	TCR	mediated	IL-2	production,	and	subsequent	
inhibition	and	deactivation,	as	well	as	diminishes	cell	growth	and	survival	signals51.	
Adapted	from	(42).	
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cell	lymphoma	and	Hodgkin	lymphoma43,46.	PD-L1	is	transcriptionally	modulated	by	c-jun	
and	increased	by	STAT3	and	through	the	inhibition	of	MEK,	the	expression	of	PD-L1	is	
subsequently	decreased47.		
	
1.4.2	Programmed	Cell	Death	Ligand-1	Expression	in	Breast	Cancer	
	
	 The	expression	of	PD-L1	on	tumour	cells	differs	from	cancer	to	cancer,	however	
its	presence	has	been	documented	in	melanoma,	ovarian,	pancreatic,	renal,	lung,	colon	
as	well	as	breast	cancer48.	In	one	study,	the	presence	of	PD-L1	on	breast	tumours	was	
observed	in	30%	of	patients	and	was	associated	with	TN	status	and	high	levels	of	TILs49.	
The	mechanisms	that	regulate	PD-L1	in	tumour	cells	are	not	fully	understood,	however	a	
few	mechanisms	have	been	described48:	On	myeloid-derived	DCs,	the	PD-1	ligation	acts	
by	negatively	regulating	cytokines	such	as	IL-6	and	MIP-1α.	On	splenic	DCs,	PD-1	acts	by	
inhibiting	the	production	of	IL-12	and	TNF-α.	When	PD-1	on	T-cells	interacts	with	PD-L1	
on	DCs	along	with	the	TCR,	inhibition	of	cytokine	production,	proliferation	and	cytolytic	
activity	occurs.	Another	study	has	shown	that	interaction	of	PD-1	and	PD-L1	cause	
anergy	in	naïve	T-cells	and	apoptosis	in	effector	T-cells50.	
In	breast	cancer,	the	role	of	PD-L1	is	less	understood:	PD-L1	is	expressed	only	on	
tumour	tissue	and	completely	absent	in	normal	tissue	of	the	same	breast52.	The	
expression	of	PD-L1	is	associated	with	a	poorer	prognosis	as	well	as	hormone	negative	
breast	cancer	and	high	grade	status52,53.	There	have	also	been	links	between	the	
mutation	in	PTEN	and	the	induction	of	PD-L1.	PTEN	is	a	protein	that	regulates	cell	
proliferation	and	acts	as	a	tumour	suppressor	and	is	also	important	in	the	regulation	of	
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the	PI3K	pathway.	In	a	study	by	Seo	et	al	(2006),	increase	in	PD-L1	has	been	shown	when	
PTEN-function	is	lost	or	mutated	in	prostate	cancer	cells50,54.	There	also	exists	a	
correlation	between	the	proliferation	marker	Ki-67	and	PD-L1	expression.	Ki-67	is	
expressed	on	both	normal	as	well	as	cancerous	proliferating	cells2.		
In	a	study	by	Ghebeh	(2006),	PD-L1	was	shown	on	41%	of	TILs	in	breast	cancer	
patients52.	PD-L1	expression	is	associated	with	larger	tumours,	and	worse	prognosis.	
Immune	defects	such	as	low	numbers	of	peripheral	blood	lymphocytes,	high	numbers	of	
T-regulatory	cells,	as	well	as	reduced	expression	of	both	HLA-class	II	and	co-stimulatory	
signal	marker	B-7	all	contribute	to	a	decrease	in	an	effective	immune	response48.	The	
expression	of	PD-L1	on	TILs	can	inhibit	T	cell	activation	and	proliferation	by	a	reverse	
signalling	mechanism	or	through	binding	to	the	PD-1	receptors	in	order	to	inhibit	other	
T-cells55,56.	The	presence	of	TILs	in	breast	cancer	specimens	has	shown	to	be	an	
important	prognostic	predictor	of	pCR	or	responsiveness	to	NAC,	a	commonly	used	
TNBC	therapy8,10.	Testing	involving	patients	with	advanced	cancers	such	as	non-small-
cell	lung	cancer,	melanoma	and	renal-cell	cancer,	showed	that	treatment	with	anti-PD-
L1	antibody	contributed	to	durable	tumour	regression	as	well	as	prolonged	stabilization	
of	disease57.		
	
1.5	Rationale	for	Targeting	the	MAPK	for	Treatment	of	TNBC	Overview	
	
There	are	a	number	of	factors	that	contribute	to	the	poor	prognosis	of	TNBC;	
these	include	activation	of	pathways	that	contribute	to	excessive	growth	and	survival	of	
tumour	cells,	one	such	pathway	is	the	MAPK	pathway.	MAPK	is	one	of	the	most	
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important	pathways	for	regulating	cell	function	due	to	its	various	roles	in	cell	
differentiation,	cellular	proliferation,	cell	migration	and	adhesion	and	cell	death58.	
Mammalian	MAPK	signaling	cascades	are	separated	into	four	major	groups:	ERK	or	
MAPK,	JNK,	p38	and	ERK	5.	The	remaining	focus	will	be	on	the	“classical”	pathway	or	the	
ERK/MAPK	pathway	(Figure	1.8).	
The	classical	pathway	is	activated	by	the	binding	of	various	ligands	such	as	
growth	factors,	mitogens,	or	hormones	to	the	cell	surface	receptor.	The	cell	surface	
receptor	then	sends	a	signal	from	the	cell	surface	to	the	nucleus	through	a	series	of	
phosphorylation	events	starting	with	the	dimerization	of	the	receptor	that	triggers	the	
autophosphorylation	of	specific	tyrosine	kinases6.	This	allows	adaptor	proteins	to	bind	
and	recruit	the	guanine	nucleotide	exchange	factor	Sos	at	the	plasma	membrane.	Sos	
then	activates	Ras	by	catalyzing	the	exchange	of	GDP	for	GTP.	Ras	then	activates	the	
serine	threonine	kinase	Raf	family	made	up	of	A-Raf,	B-Raf	and	Raf-1,	which	in	turn	
phosphorylate	MEK	1	and	MEK	2	(MAPK	kinase/ERK	kinase).	Like	Ras,	Raf	can	send	
signals	through	MEK-dependent	or	MEK-independent	pathways;	however,	the	only	
downstream	targets	of	MEK	1	and	MEK	2	are	ERK	1	and	ERK	259.	MEKs	share	79%	amino	
acid	identity	and	are	both	equally	able	to	phosphorylate	ERK	1/2.	Once	phosphorylated,	
ERK	1/2	are	able	to	enter	the	nucleus	and	activate	transcription	factors	and	regulatory	
proteins	that	are	responsible	for	a	diverse	number	of	cellular	responses	such	as	cell	
proliferation,	survival,	differentiation,	motility	and	angiogenesis60,61.	ERK	1	and	ERK	2	are	
85%	homologous	with	two	phosphoacceptor	sites,	tyrosine	and	threonine,	which	are		
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Figure	1.8:	The	mitogen-activated	protein	kinase	pathway.	
	
MAPK	pathway	is	activated	by	attachment	of	ligands	(growth	factors,	mitogens,	
hormones)	to	the	cell	surface	EGFR.	The	signal	causes	the	dimerization	of	the	EGFR	that	
then	triggers	autophosphorylation	of	specific	tyrosine	kinases.	Sos	is	bound	and	
recruited	by	adaptor	proteins	and	then	activates	Ras	by	exchanging	GDP	for	GTP.	Ras	
then	activates	the	Raf	family,	which	phosphorylates	MEK	1	and	MEK	2,	and	in	turn	
phosphorylates	ERK	1	and	ERK	2,	which	can	then	enter	the	nucleus	and	activate	
transcription	factors	and	regulatory	proteins.	Adapted	from	(43).	
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phosphorylated	to	activate	the	kinases.	Both	ERK	1	and	ERK	2	are	ubiquitously	
expressed,	but	their	abundance	in	tissue	is	varied62.			
	Ras	belongs	to	a	group	of	GTPases	that	help	mediate	the	integration	of	signals	
generated	by	the	pathway	and	therefore	is	a	therapeutic	target	with	therapies	aimed	at	
disrupting	its	expression	and/or	function.	There	are	three	Ras	family	genes	(KRas,	NRas,	
and	HRas)	and	mutations	in	the	Ras	family	are	known	to	be	crucial	for	the	development	
of	human	tumours.	Indeed	the	Ras	oncoprotein	is	one	of	the	main	regulators	of	growth	
factor-induced	cell	survival	in	both	normal	and	cancer	cells63,64.	In	the	cascade,	Ras	
activates	Raf1	in	a	GTP-dependent	manner59.		Given	the	complexity	of	this	pathway	and	
its	importance	in	the	regulation	of	cellular	processes,	scaffolding	proteins	are	
responsible	for	pathway	organization.	The	scaffold	proteins	bind	and	sequester	various	
MAPK	components	and	help	coordinate	efficient	activation	of	the	pathway	in	response	
to	stimuli65.	
1.5.1	Mitogen-Activated	Protein	Kinase	Pathway	and	Breast	Cancer	
	
The	MAPK	pathway	is	found	to	directly	contribute	to	the	protection	of	tumours	
through	two	ways:	1)	Growth	and	2)	Cell	survival59.	Of	the	three	Ras	family	genes	only	
small	minorities	of	tumours	from	BC	patients	have	mutations	(KRas	is	mutated	in	just	
1.5%	of	BCs)66.	Raf	mutations	have	also	been	linked	to	human	cancers,	and	regardless	of	
its	mutation	status,	Raf	is	activated	in	tumours	causing	increased	proliferation	and	
survival.	Of	the	three	isoforms	of	Raf,	BRaf	is	mutated	in	approximately	3%	of	the	
tumours	in	BC	patients67.	Despite	the	rarity	of	these	mutations,	many	in	the	literature	
have	discussed	the	MAPK	pathway	and	its	importance	in	breast	cancer:	For	instance	the	
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majority	of	basal-like	breast	cancers	show	high	levels	of	EGFR	and	due	to	these	high	
levels,	results	in	hyperactivation	of	the	MAPK	pathway6.	Interestingly,	in	mouse	models,	
mammary	tissue-specific	expression	of	activated	Ras	is	enough	to	generate	breast	
carcinoma68.	In	one	study	by	Loi	and	colleagues	(2015),		genomic	or	transcriptomic	
activation	of	the	MAPK	is	also	associated	with	decreased	levels	of	TILs,	which	has	been	
shown	to	lead	to	a	poorer	prognosis	for	TNBC	patients8.	
	
1.5.2	Implications	of	Targeting	the	Mitogen-Activated	Protein	Kinase	Pathway	
	
There	are	drawbacks	to	inhibiting	such	a	widespread	pathway.	Because	a	large	
number	of	normal	cells	rely	on	the	continued	activation	of	MAPK,	inhibition	could	prove	
toxic.	However,	cross-talk	between	the	pathways,	such	as	the	PI3K	pathway,	may	
become	activated	in	response	to	MAPK	inhibition	helping	to	preserve	homeostasis69.	
One	of	the	benefits	of	MEK-specific	inhibitors	is	that	their	only	direct	downstream	
targets	are	ERK	1/2	making	it	an	attractive	target	for	pathway	inhibition.			
	
1.6	The	Mitogen-	Activated	Protein	Kinase	Pathway	Inhibitors		
	
	 There	are	a	number	of	inhibitors	on	the	market	that	can	inhibit	the	MAPK	
pathway,	and	these	vary	depending	on	the	part	of	the	pathway	targeted.	There	are	19	
MEK	specific	inhibitors,	as	well	as	many	others	for	RAF,	p38,	JNK,	and	ERK.	In	the	course	
of	this	research,	five	MAPK	inhibitors	were	used:	PD98059,	U0126,	PD0325901,	
Selumetinib	(AZD6244)	and	Trametinib	(GSK1120212)70.	These	inhibitors	are	specific	for	
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the	MEK	proteins,	however	their	specific	targets	vary;	with	some	specific	for	MEK	1	and	
others	inhibiting	both	MEK	1	and	2.	Of	these	five,	Sel	and	Tram	are	the	most	clinically	
relevant	in	current	cancer	research.	
	
1.6.1	U0126	
	
U0126	is	a	pan	MEK	inhibitor,	effectively	blocking	both	MEK	1	and	MEK	2	with	an	
IC50	of	0.07	µM.	U0126	is	a	non-competitive	inhibitor	with	respect	to	MEK,	ATP	and	
ERK71.	In	vitro,	U0126	functionally	antagonizes	AP-1	transcriptional	activity	and	blocks	a	
variety	of	cytokines	and	metalloproteinases	involved	in	the	inflammatory	process,	also,	
U0126	decreases	T-cell	activation	and	it	down-regulates	IL-2	mRNA	levels72.		
U0126	has	been	tested	extensively	both	in	vitro	and	in	vivo	and	has	shown	
consistent	results	in	its	ability	to	inhibit	the	MAPK	pathway.	U0126	also	has	the	ability	to	
rescue	estrogen	receptor	expression	in	BC	cells73.	However,	in	many	TNBC	lines	such	as	
MDA-MB-231,	BT-20,	MDA-MB-468	and	HS578T	cells,	which	exhibit	site-specific	
methylation	of	CpG	islands	in	the	ERα	promoter,	treatment	with	a	demethylating	agent	
is	required	to	obtain	re-expression	of	the	estrogen	status74.	
U0126	has	also	been	shown	to	increase	CIITA	levels	especially	when	in	the	
presence	of	IFN-γ75,76.	These	studies	also	suggest	that	CIITA	expression	is	negatively	
regulated	by	ERK	and	p38	MAPK	signals	in	macrophages	and	dendritic	cells.	Previous	
research	in	the	Drover	lab	has	shown	that	the	use	of	U0126	results	in	the	decrease	of	
surface	HLA-DR	expression77.	Explanations	for	this	could	be	that	MAPK	activation	up-
regulates	cell	surface	markers	such	as	CD40,	CD80,	CD86	and	HLA-DR	therefore	the	
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antigen	presentation	process	is	enhanced78.	U0126	has	also	been	shown	to	decrease	PD-
L1	levels	in	melanoma	cells47.	
	
1.6.2	PD98059	
	
PD98059	is	a	highly	selective	MEK	1	inhibitor	with	no	direct	inhibition	of	ERK	1	or	
ERK	2.	It	is	non-ATP	competitive	and	has	an	IC50	of	2	µM.	PD98059	inhibits	neither	
MAPK	homologs	JNK	and	p38,	nor	Raf	kinase,	cAMP-dependent	kinase,	protein	kinase	C,	
v-Src,	epidermal	growth	factor	(EGF)	receptor	kinase,	insulin	receptor	kinase,	PDGF	
receptor	kinase,	or	phosphatidylinositol	3-kinase70.		
PD98059	is	incapable	of	inhibiting	wild	type	MEK	1	that	has	been	activated	
through	Raf-mediated	phosphorylation,	suggesting	that	PD98059	can	only	bind	to	the	
inactive	or	unphosphorylated	form	of	MEK	171.	PD98059	has	also	been	shown	to	
increase	HLA	class	I	in	gastric	and	ESCC	cell	lines79.	
	
1.6.3	PD0325901	
	
PD0325901	is	a	pan	inhibitor	of	MEK	with	an	IC50	of	0.33	nM	and	is	non-ATP	
competitive.	PD0325901	is	approximately	500-fold	more	potent	than	1st	generation	MEK	
inhibitor	CI-104070.	A	single	oral	dose	at	25	mg/kg	shows	greater	than	50%	inhibition	of	
ERK	at	24	hours	post-dose.	In	mouse	studies,	a	week	of	oral	administration	shows	no	
tumour	growth	in	those	inoculated	with	BRAF-mutation-containing	papillary	thyroid	
cancer	(PTC)	cells80.	The	mechanism	of	action	for	PD0325901	allows	for	inhibition	of	
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MEK	without	perturbing	the	ATP	site.	It	has	been	proposed	that	this	inhibitor	induces	a	
conformational	change	in	the	protein	that	traps	the	kinase	activation	loop,	and	when	
bound,	the	inhibitor	partially	occludes	the	MEK	1	catalytic	site	therefore	not	allowing	
ERK	to	access	the	catalytic	pocket	and	become	phosphorylated63.	
In	human	melanoma	clinical	trials,	when	given	a	dosage	of	≥2	mg	bi-daily	(BID),	
PD0325901	decreased	phosphorylated	ERK	by	60%	as	well	as	decreased	the	proliferation	
marker,	Ki6780.	Despite	its	advances,	PD0325901	was	discontinued	from	clinical	trials	
due	to	its	toxicities	including	retinal	vein	occlusions	and	neuropathy	due	to	its	ability	to	
cross	the	blood	brain	barrier81.	Because	of	the	discontinuation	of	this	drug	in	clinical	
trials,	it	was	used	only	in	the	beginning	of	this	research.		
	
1.6.4	Selumetinib	(AZD6244)	
	
Selumetinib	(AZD6244)	(Astra	Zeneca)	is	a	highly	selective	second	generation	
MEK	1	inhibitor	with	an	IC50	of	14	nM.	Selumetinib	is	not	competitive	with	ATP	and	can	
inhibit	ERK	phosphorylation	at	concentrations	of	40	nM	or	less.	Selumetinib	is	highly	
selective	and	does	not	affect	p38,	c-jun,	PI3K	or	MEK5/ERK5	pathways70.	Selumetinib	is	
used	in	clinical	trials	for	treatment	of	cancers	ranging	from	stage	1-3	including	NSCLC,	
gallbladder	carcinoma,	rectal	cancer,	thyroid	cancer,	colon	cancer,	as	well	as	metastatic	
breast	cancer	(among	others)82.	
In	a	study	by	Favata	and	colleagues	(1998),	a	correlation	between	sensitivity	to	
Selumetinib	and	Ras	and	Raf	mutations	was	shown71.	Although	less	common	in	breast	
cancer,	with	only	4%	harboring	Ras	mutations	and	7%	for	Raf,	they	are	associated	with	a	
	 35	
poor	prognosis83.	TNBC	cell	line	MDA-MB-231	has	mutations	present	in	both	BRAF	and	
KRAS,	which	suggests	it	will	be	sensitive	to	Selumetinib	treatment84.		
	
1.6.5	Trametinib	(GSK1120212)	
	
Trametinib	(GSK1120212)	is	a	highly	specific	and	potent	MEK	1/2	inhibitor	with	
an	IC50	0.92	nM-3.4	nM.	Trametinib	inhibits	the	kinase	activity	of	MEK	1/2	and	thereby	
prevents	Raf-dependent	MEK	phosphorylation.	Like	Selumetinib,	results	using	this	
inhibitor	are	most	pronounced	in	cell	lines	with	BRAF	or	Ras	mutation70.	It	is	more	
potent	than	both	Selumetinib	and	PD0325901	and	when	administered	in	vivo	orally	at	
0.3	-1	mg/kg	for	a	two-week	duration,	is	able	to	inhibit	tumour	growth85.	
This	inhibitor	has	benefits	compared	to	the	others	by	having	a	long	circulating	
half-life	with	continued	inhibition	after	24	hours.	Trametinib	differs	from	PD0325901	in	
that	it	does	not	significantly	penetrate	intact	brain81.	Trametinib	has	been	shown	to	
have	a	33%	response	rate	in	Braf-mutant	melanoma,	with	median	progression-free	
survival	in	patients	of	5-7	months,	and	in	the	subset	without	brain	metastases	it	was	7-4	
months86.		
When	AT3ova	and	4T1.9	mouse	TNBC	cells	were	treated	with	100	nM	Trametinib,	it	was	
shown	that	it	could	potentiate	the	effect	of	interferon-gamma	on	MHC	class	I,	MHC	class	
II	and	PD-L1	expression	in	vivo	and	in	vitro,	indicating	its	usefulness	as	a	potential	
immunotherapeutic	drug	for	TNBC8.			
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1.7	Rationale	and	Hypothesis	
	 Immunotherapy	has	been	gaining	more	attention	and	importance	in	cancer	
research,	due	to	its	promising	ability	to	target	and	destroy	tumours	that	may	otherwise	
lack	target	molecules	or	be	resistant	to	current	treatment	options.		For	cancers	with	
limited	targets	available	for	treatment,	such	as	TNBCs,	additional	options	in	the	form	of	
immunotherapy	such	as	checkpoint	and	pathway	inhibitors	that	can	modulate	immune	
markers,	is	fast	becoming	a	real	possibility.	By	helping	our	immune	systems	better	
identify	tumour	cells	while	simultaneously	decreasing	immune	escape,	even	cancers	that	
lack	targets	for	conventional	therapies	have	the	potential	for	pharmaceutical	
intervention.		
	 With	down-regulation	of	HLA	class	I	as	a	mechanism	of	immune	escape	in	so	
many	tumour	cells,	the	rescue	or	up-regulation	of	HLA	status	could	have	potential	
immunotherapeutic	effects	by	increasing	tumour-antigen	presentation	to	surrounding	
TIL’s.	Conversely,	the	up-regulation	of	certain	inhibitory	molecules	such	as	PD-L1	on	the	
tumour	surface	could	have	adverse	effects	by	decreasing	T-cell	activation	and	
proliferation,	thereby	aiding	the	tumour	in	immune	escape.		
As	previous	studies	have	shown,	MAPK	becomes	hyperactivated	in	TNBC	and	may	
play	a	role	in	the	modulation	of	HLA	and	PD-L1	expression.		Thus,	we	hypothesized	that	
MEK	inhibition	and,	subsequently,	inactivation	of	phosphorylated	ERK	1/2	may	alter	
tumour	expression	of	these	markers,	possibly	resulting	in	desirable	effects,	that	is,	
increased	HLA	expression	and	diminished	PD-L1	expression.		Also,	due	to	the	importance	
of	the	IFN-γ	pathway	in	anti-tumour	immunity	and	its	role	in	the	regulation	of	HLA	and	
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PD-L1	expression,	we	queried	the	effects	of	inhibition	of	MAPK	on	IFN-γ	inducible,	as	
compared	to	constitutive	HLA	and	PD-L1	expression.		
Objectives:	
1. As	previous	research	in	the	Drover	laboratory	showed	that	the	MEKi,	U0126,	
diminished	cell	surface,	but	not	intracellular	HLA-DR	expression	on	the	TNBC	
line,	MDA-MB-231c10A,	it	was	important	to	determine	the	effects	(if	any)	of	
U0126	on	HLA	class	I	and	PD-L1	expression	in	the	same	cell	line.	The	second	
part	of	this	objective,	is	to	determine	if	other	MEKi(s)	similarly	modulate	of	
these	molecules	in	MDA-MB-231c10A.	
2. To	determine	the	effects	of	MEKi(s)	on	both	constitutive	and	IFN-γ	induced	
HLA	and	PD-L1	expression	in	other	TNBC	lines.	
3. To	determine	the	effects	of	MEKi(s)	on	constitutive	and	IFN-γ	-induced	HLA	
and	PD-L1	expression	in	other	cancer	lines.		
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Chapter	2:	Materials	and	methods		
	
2.1	Cell	Culture	
	
Several	established	TNBC	cell	lines	were	used	in	this	research:	MDA-MB-231,	
MDA-MB-468,	BT-20,	HS578T,	normal	breast	line:	HS578Bst	and	three	non-breast	cancer	
lines:	MDA-MB-435,	a	melanoma	line87,	colon	cancer	line	HT-29	and	EBV	transformed	
lymphoblastoid	line	SAVC.	A	clone	of	MDA-MB-231,	henceforth	referred	to	as	MDA-
231c10A,	was	also	used.	MDA-231c10A	was	grown	in	MEM	(supplemented	with	2	mM	L-
glutamine	(Invitrogen,	Cat#	25030-164),	and	2	mM	antibiotic	antimycotic,	(A/A)	
(Invitrogen,	Cat#	15240-112)	and	estrogen-depleted	FBS.	the	remaining	lines	were	
grown	in	CM	consisting	of	IMDM,	supplemented	with	10%	heat	inactivated	FCS	
(Invitrogen,	Cat#	12600-44),	2	mM	L-glutamine	(Invitrogen,	Cat#	25030-164),	and	2	mM	
antibiotic	antimycotic,	(A/A)	(Invitrogen,	Cat#	15240-112).	The	cancer	cell	lines	were	
originally	purchased	form	the	ATCC,	while	the	B-cell	line	was	obtained	through	the	10th	
International	Histocompatibility	Workshop.	Cultures	were	grown	in	10	cm2	tissue	culture	
plates	(Falcon,	Becton	Dickinson	(BD)	Biosciences)	at	37°C	in	7%	CO2	atmosphere.	
Cultures	were	refreshed	every	5	days	with	CM	and	cells	were	harvested	when	80-90%	
confluent.	B-cell	line	was	grown	as	suspension	cultures	in	IMDM.	
	
2.2	Harvesting	of	Adherent	Cells	
	
	 Media	was	aspirated	from	culture	plates	using	vacuum	filtration.	Cells	were	
washed	using	5-6mls	of	1X	sterile	PBS.	Cells	grown	in	IMDM	were	detached	from	plate	
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using	0.25%	Trypsin-EDTA	(Invitrogen,	Cat#	25200-114)	and	incubated	at	37°C	for	1-2	
mins	after	which,	reaction	was	ceased	by	addition	of	CM.	Additionally,	cells	grown	in	
MEM	used	phenol-red	free	2.5%	Trypsin.	Medium	was	pipetted	back	and	forth	to	ensure	
maximum	cell	detachment	and	collection,	The	cells	were	then	transferred	to	15	mL	
centrifuge	tube	and	centrifuged	at	500	x	g	at	8°C	for	7	minutes.	After	centrifugation	and	
removal	of	supernatant,	the	pellet	was	re-suspended	in	6-7	mls	of	medium	and	
centrifuged	again	at	the	same	settings.	After	the	second	wash,	cells	were	re-suspended	
in	6mls	of	CM	and	counted	using	a	haemocytometer	and	phase	contrast	microscope.	
Cells	were	re-plated	at	a	density	of	approximately	5x105	in	a	10	cm2	culture	dish	
containing	10	mls	of	CM.	
	
2.3	MEK	Inhibitor	Treatment	
	
Cell	lines,	plated	in	6-well	tissue	culture	plates	(Falcon,	Corning	Life	Sciences,	
Cat#	353046)	at	a	density	of	2.5X105	cells/well	were	incubated	for	24	hours,	after	which	
the	medium	was	exchanged	for	fresh	CM.	Preparations	of	MEK	inhibitors,	as	described	
below	were	added	directly	to	wells.		MEK	inhibitors;	Selumetinib	(AZD6244)	(Cat#	S1008,	
50	mg),	Trametinib	(GSK1120212)	(Cat#	S2673,	5	mg),	and	PD0325901	(Cat#	S1036,	10	
mg),	PD98059	(Cat#	S1177)	were	purchased	from	Selleckchem.com	and	U0126	was	
purchased	from	Calbiochem	(Cat	#	CAS	109511-58-2).	
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Table	2.1:Human	cell	lines	used	in	this	study	
Cell	Line	 Identification	 Cell	Type	 Cancer	classification	 Receptor	Expression	
MDA-MB-
231	
ATCC	
HTB-26	
TNBC	 Adenocarcinoma	
Basal	B	
ER-,	PR-,	HER2-	
MDA-MB-
468	
ATCC	
HTB-132	
TNBC	 Adenocarcinoma	
Basal	A	
ER-,	PR-,	HER2-	
BT-20	 ATCC	
HTB-19	
TNBC	 Carcinoma	
Basal	A	
ER-,	PR-,	HER2-	
HS578T	 ATCC	
HTB-126	
TNBC	 Carcinoma	
Basal	B	
ER-,	PR-,	HER2-	
MDA-MB-
435	
ATCC	
HTB-129	
Melanoma	 Ductal	carcinoma1	 N/A2	
HT-29	 ATCC	
HTB-38	
Colon	Cancer	 Colorectal	adencarcinoma	 N/A	
HS578Bst	 ATCC	
HTB-125	
Normal	Breast	
Tissue	
Normal	breast	tissue	 N/A	
SAVC	 10th	
international	
histocompatibi
lity	workshop	
EBV	
transformed	
lymphoblastoid	
line	
	
Blood	sample	 N/A	
	 	
																																																						
1	MDA-MB-435	was	previously	classified	as	a	TNBC,	but	is	now	accepted	as	a	melanoma	
line.	
2	“Not	applicable”	for	this	section	
	 41	
5	mM	Stock	solutions	were	achieved	by	dissolving	each	drug	in	DMSO	and	stored	
in	aliquots	at	-80°C.	Cells	were	treated	for	a	time	period	ranging	4-72	hours,	with	most	
data	collected	from	72hr	experiments.	Drugs	were	used	at	clinically	relevant	and	optimal	
concentrations	suggested	by	literature	and	product	website	as	well	as	determined	by	
crystal	violet	viability	assays	done	in	lab	to	determine	drug-induced	cytotoxicity	(Chapter	
2.9).	All	drug	treatments	were	matched	with	DMSO	vehicle	controls	1hr	prior	to	IFN-γ	
addition.		
	
2.4	Interferon	Gamma	Stimulation		
	
Since	IFN-γ	is	known	to	up-regulate	HLA	class	I,	HLA	class	II	and	PD-L1,		its	
addition/absence	was	used	to	compare	constitutive	and	induced	expression	of	HLA	and	
PD-L1	in	cell	lines	treated	with	MEKi(s).	One	1hr	after	drug	treatment,	100	units	of	
human	recombinant	IFN-γ	(BD	Biosciences,	55461)	was	added	to	each	well	and	
incubated	for	the	desired	time	period.	Optimal	IFN-γ	concentration	for	up-regulation	of	
HLA	was	achieved	through	previous	experiments	(Ahmed	Mostafa,	PhD	thesis,	2014).		
	 	
2.5	Flow	cytometry	
	
2.5.1	Cell	Surface	Assay	
	
The	effects	of	MEKi(s)	on	HLA	class	I,	HLA	DR	and	PD-L1	surface	expression	was	
detected	by	flow	cytometry.	Adherent	cells	were	washed	in	PBS,	detached	with	trypsin	
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and	harvested	according	to	above	procedure	(Chapter	2.2).	After	the	first	centrifugation,	
cells	were	resuspended	in	Fluorescence	Activated	Cell	Sorting	Buffer	(FACS	buffer)	
comprised	of	0.2%	FBS,	and	0.02%	sodium	azide	(NaN3)	in	PBS.	After	washing,	100	µl	of	
cell	suspension	containing	a	minimum	of	1X105	was	added	to	5	ml	polystyrene	round	
bottom	tubes	(Falcon,	BD).	Primary	antibodies	were	diluted	in	FACS	buffer	to	their	
optimal	concentrations	and	25	µl	was	added	to	100	µl	cell	suspension	and	incubated	for	
30	minutes	on	ice	at	4°C.		
	 After	this	primary	incubation,	cells	were	washed	twice	in	2	mls	FACS	buffer	and	
centrifuged	at	600	x	g	for	5	minutes	at	8	degrees.	Supernatant	was	decanted	and	25	ul	
of	secondary	antibody	goat	anti-mouse	immunoglobulin-G	labeled	with	phycoerythrin	
fluorochrome,	diluted	1/40	in	FACs	buffer	was	added	to	each	tube.	Cells	were	incubated	
on	ice	in	the	dark	for	a	further	30	minutes.	After	this	incubation,	cells	were	washed	and	
centrifuged	twice	and	then	fixed	with	150	µl	1%	paraformaldehyde	(PFA)	(Sigma)	diluted	
in	PBS.	Cells	were	analyzed	for	10,000	events	using	a	FACStarPlus	flow	cytometer	
(Becton-Dickinson)	and	CellquestPro	software	(Becton-Dickinson).	
	
2.5.2	Data	Analysis	and	Interpretation		
	
	 MFI	and	the	percentage	of	positive	cells	were	measured	used	Cellquest	Pro	
software	in	order	to	quantify	the	amount	of	cell	surface	expression	of	HLA-DR,	HLA	class	
I	and	PD-L1.	Test	results	were	considered	positive	if	MFI	was	at	least	twice	the	negative	
control	MFI.	Ratio	of	treated/untreated	was	obtained	by	dividing	relative	test	values	by	
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the	relative	DMSO	control	given	by	the	formula:	(treatment	MFI	–	control	MFI)	/	(DMSO	
MFI	-	control	MFI).	Test	values	were	compared	to	that	of	the	relative	controls,	which	
were	given	the	value	of	1.	Those	with	values	of	1	were	designated	“no	effect”,	and	those	
with	values	greater	than	1	were	concluded	to	have	a	positive	or,	up-regulatory	effect	on	
surface	expression.	A	Student	T-Test	was	used	to	determine	statistical	significance	
between	the	controls	and	the	drug-treated	samples.	A	one-way	Anova	paired	with	a	
Tukey	HSD	test	was	used	to	compare	the	inhibitor-mediated	effects	to	one	another.	
Statistics	were	assessed	on	Microsoft	Excel.	A	p-value	of	less	than	or	equal	to	0.05	was	
determined	to	be	of	significance.		
	
2.6	SDS-PAGE	Western	Blotting	
2.6.1	Lysate	Preparation	
	
	 Cells	were	plated	in	6-well	tissue	culture	dishes	at	a	density	of	2.5x105	and	
treated	with	optimal	concentrations	of	MEKi,	controls	and/or	IFN-γ	as	previously	
described	in	section(s)	2.3	&	2.4.	Once	ready,	medium	was	removed	via	vacuum	
filtration,	cells	were	rinsed	in	2	mls	PBS,	followed	by	the	addition	of	100-200	µl	RIPA	was	
added	to	each	well.	RIPA	buffer	prepared	immediately	before	use,	consisted	of	0.5%	
sodium	deoxycholate	(Biochemical,	43035),	0.1%	SDS	(BioRAD,	161-0301),1%	NP40	
(Sigma,	100F-39211)	in	PBS	at	a	pH	of	7.3,	and	protease	inhibitors	aprotinin	(5	mg/ml)	
(Sigma,	A4529),	leupeptin	(10	mg/ml)	(Sigma,	L202),	pepstatin	A	(2	mg/ml)	(Sigma,	
P5318),	2	M	PMSF	(Sigma,	P7626)	and	halt	phosphate	inhibitor	cocktail	
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(Thermoscientific,	78420).	Cells	were	then	scraped	from	the	plate	using	a	sterile,	plastic	
cell	scraper,	transferred	to	1.5	ml	microfuge	tubes	and	centrifuged	at	11,000	x	g	for	15	
mins	at	4°C.	The	pellet	was	discarded	and	the	supernatant	was	collected,	labeled	and	
stored	at	-80°C	for	electrophoresis	and	Western	blotting.		
	
2.6.2	Quantification	of	Cell	Lysate	Protein	Concentration(s)	
	 Protein	concentration	of	cell	lysates	was	quantified	using	a	BCA	protein	assay	kit	
(ThermoScientific),	according	to	the	manufacturer’s	instructions.	The	assay	was	set	up	
by	adding	50	µl	of	each	sample,	diluted	1:10	to	5	ml	polystyrene	round-bottom	tubes	
(Falcon,	Becton	Dickson	Bioscience)	and	50	µl	of	BSA	standards,	to	ten	separate	5	ml	
polystyrene	round-bottom	tubes.		BSA	concentrations,	0	µg,	31.25	µg,	62.5	µg,	125	µg,	
250	µg,	and	500	µg,	were	done	in	duplicate.	1ml	of	BCA	protein	assay	working	reagent	
was	added	to	each	tubes	at	a	ratio	of	50:1	Reagent	A:	Reagent	B.	All	tubes	were	
incubated	at	37°C	for	30mins	and	then	read	using	Spectrophotometer	(Beckman	Coulter	
DU→	530)	at	wavelength	562		nM.	Protein	concentrations	were	calculated	from	the	
standard	curve.	
	
2.6.3	Electrophoresis	of	Cell	Lysates	
	
	 An	8%	running	gel	was	prepared	using	1.25	ml	water,	1ml	acrylamide,	1	ml	
running	buffer	(1.5	M	Tris	HCl	Buffer	(BioRad))	pH	8.8,	40	µl	10%	SDS,	40	µl	10%	APS,	
and	2	µl	Temed.	The	stacking	gel	was	prepared	using		860	µl	water,	250	µl	acrylamide	
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(BioRad),	380	µl	stacking	buffer	(0.5	M	Tris	HCl	buffer	(BioRad))	pH	6.8,	15	µl	10%	SDS,	15	
µl	APS	(BioRad),	1.5	µl	Temed	(BioRad))	
	 Samples	were	loaded	using	equal	amounts	of	protein	in	10-40	µl	depending	on	
the	amount	of	protein	in	the	appropriate	well	of	each	lane	alongside	4	µl	of	protein	
ladder	(BLUeye	Prestained	Protein	Ladder	Cat#	PM007-0500)	in	order	to	determine	
band-size.	Electrophoreses	was	performed	at	100V	for	1hr	45mins	using	a	Mini-
PROTEIN→	Cell	electrophoresis	chamber	(BioRad)	containing	running	buffer	(consisting	of	
25	mM	Tris	HCl	pH	8.8,	0.1%	SDS,	190	mM	gylcine	(Sigma)).		
	
2.6.4	Electrophoretic	Protein	Transfer	
	
Proteins	were	transferred	to	nitrocellulose	membrane	as	follows:	nitrocellulose	
membranes,	filter	paper	and	foam	pads	were	pre-soaked	in	transfer	buffer	(25	mM-	Tris	
HCL	pH	8.8,	190	mM	glycine,	20%	methanol)	for	15mins	prior	to	transfer.	Gels	were	
carefully	removed	from	electrophoresis	apparatus	and	submersed	in	transfer	buffer.	The	
transfer	sandwich	cassette	was	then	assembled	in	this	order:	black	plastic	base,	foam	
pad,	filter	paper,	filter	paper	with	gel,	nitrocellulose	membrane,	filter	paper,	clear	plastic	
base.	The	sandwich	cassette	was	then	placed	into	the	Trans-blot	cell	(BioRad)	with	a	cool	
pack,	set	upon	a	magnetic	stirrer	and	run	at	100V	for	1hr.			
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Table	2.2:	Primary	antibodies	used	in	this	study	
Antibody	 Isotype	 Specificity	 Concentration	 Sources	
Flow	 W.B	 I.F	
W6/32	
	
Mouse	IgG2a	 HLA	class	I	 1/25	 1/25	 1/25	 In	house	
MUB2037P	 Mouse	IgG2a	 HLA	class	I	
heavy	chain		
NA3	 1/1000	 NA	 Nordic	MUbio	
L243	
	
Mouse	IgG2a	 HLA-DR	 2.5	µg/ml	 NA	 2.5	µg/ml	 In	house	
MIH2	
ab109052	
Mouse	IgG1	 PD-L1	 5	µg/ml	 NA	 NA	 Abcam		
	
E1L3N	
#13684	
Rabbit	IgG	 PD-L1	 NA	 1/1000	 	 Cell	Signaling		
	
ab58810*	 Rabbit	IgG	 PD-L1	 NA	 1	µg/ml	 NA	 Abcam		
	
Phospho-
p44/42	MAPK	
(ERK	1/2)	(Thr	
202/Tyr	204)	
9101	
	
Rabbit	IgG	 pERK	 NA	 1/500	 NA	 Cell	Signaling	
	
(E-4)	
sc-7383	
Mouse	IgG2a	 pERK	 NA	 1/500	 NA	 SantaCruz	
Biotechnology	
	
K-23	
sc94	
Rabbit	IgG	 ERK-1	total	 NA	 1/5000	 NA	 SantaCruz	
Biotechnology	
	
IgG1	 Mouse	IgG1	 Control	 5	µg/ml	 NA	 5µg/ml	 eBioscience	
Clone	P3.6.2.8	
Cat#	16-4714-85	
NSG2a		 Mouse	
IgG2a		
Control	 5	µg/ml	 NA	 5µg/ml	 Local	source	
B-7	 Mouse	IgG2a	 Alpha-tubulin	 NA	 250	
ng/ml	
NA	 Santa	Cruz	
Biotechnology	
Ab8245	 Mouse	IgG1	 GAPDH	 NA	 1	ng/ml	 NA	 Abcam	
	
	
	
	
	
	
	
																																																						
3	Not	applicable	to	this	section	
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2.6.5	Detection	of	Proteins	
	
	 After	transfer	was	complete,	nitrocellulose	membranes	were	treated	with	
blocking	buffer	(5%	milk	powder	in	Tris-buffered	saline	(TBS-T)-Tween	20	(0.15	M	NaCl,	
0.05	M	Tris	pH	7.2-7.6,	0.05%	Tween-20))	and	set	on	a	shaker	for	1hr.	Primary	antibody	
optimally	diluted	in	5ml	blocking	buffer	was	added	to	each	blot,		in	a	sealed	container	
and	placed	on	a	shaker	at	4°C	and	left	overnight.	Membranes	were	then	washed	three	
times	for	5mins	each	with	TBS-Tween-20.		Optimally-diluted	secondary	antibody,	
conjugated	with	horseradish	peroxidase	was	added	to	the	membrane	and	placed	on	a	
shaker	for	1hr.	Membranes	were	washed	3	times	for	ten	minutes/wash	followed	by	
signal	detection	using	Immobilon	Western	Chemiluminescent	HRP	Substrate	(Millipore).	
ImageQuant	LAS	4000	Station	(GE	Health	Care)	was	used	to	image	the	blots.	
	
2.6.6	Reprobing	Membranes	
	
To	strip	blots	for	reprobing,	membranes	were	washed	three	times	for	10mins	
with	a	TBS	stripping	buffer	(pH	2.0),	followed	by	three	washes	with	TBS-Tween-20	for	
10mins	each.	
	
2.7	Immunocytochemisty		
2.7.1	Chamber	Slide	Set-Up		
	
Cells	were	grown	in	8-well	or	16-well	chamber	slides	(Cat	#	154534	
ThermoScientific)	at	2.5x104	or	1.5x104	cells/well	respectively	with	experimental	 	
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Table	2.3:	Secondary	antibodies	used	for	Western	blotting	
Antibody	 Isotype	 Specificity	 Concentration	 Source	
HRP-conjugated	
affiniPure	f(ab)2	
fragment	goat	
anti-mouse	(GAM)	
Fc	specific			
Goat	IgG	 Mouse	IgG	 1/10,000	 Jackson	
Immnoresearch	
HRP-conjugated	
affiniPure	f(ab)2	
fragment	goat	
anti-rabbit	(GAR)	
Fc	specific			
Goat	IgG	 Rabbit	IgG	 1/10,000	 Jackson	
Immnoresearch	
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treatment	added	for	a	specific	time	period.	Then	media	was	aspirated	and	cells	were	
washed	with	PBS	and	left	to	air	dry	overnight,	followed	by	fixation	with	acetone	(15mins	
at	-20°C),	methanol	(10mins	at	-20°C	or	paraformaldehyde	(15mins	4°C).	
	
2.7.2	Cytocentrifuge	Preparation	
	
Cells	were	counted	using	haemocytometer	and	an	aliquot	containing	6x105	cells	
was	added	to	a	15	ml	centrifuge	tube	and	centrifuged	at	500	x	g	for	7min	at	8°C.	After	
spinning,	media	was	removed	and	the	pellet	was	re-suspended	in	6mls	of	PBS.	500	µl	of	
cell	sample	(5x104	cells)	was	added	to	the	cytocentrifuge	sample	chamber	and	cells	were	
adhered	to	the	slide	by	centrifuging	at	500	x	g	for	five	minutes.	Cells	were	adhered	to	a	
particular	spot	on	the	slide	surface	due	to	a	piece	of	filter	paper	(Shandon	Inc.,	Pittsburg,	
PA)	assembled	between	the	chamber	and	the	slide.	Once	centrifuged,	slides	were	left	to	
dry	overnight.		
	
2.7.3	Immunofluorescence	Staining	
	 Cells	were	rehydrated	by	adding	PBS	for	5mins,	then	were	blocked	for	1hr	using	
15%	goat	serum	in	PBS.	Then	100	µl	of	primary	antibody,	optimally	diluted	in	washing	
buffer	(PBS	containing	0.5%	bovine	serum	albumin	(BSA)	(Sigma),	0.05%	Tween-20),	was	
added	to	each	well	and	incubated	for	1hr	at	room	temperature	in	a	humid	chamber.	
Slides	were	then	washed	3	times	for	5mins	each	with	washing	buffer	in	a	Coplin	jar	on	a	
stir	plate	with	a	small	magnetic	stirrer.	Slides	were	then	incubated	for	1hr,	in	the	dark,	
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with	secondary	antibody	(Alexafluor-conjugated),	followed	by	three	5min	washes	with	
washing	buffer	followed	by	a	20min	wash	with	PBS.	Slides	were	mounted	using	
VECTASHEILD	mounting	medium	with	DAPI	(Vector	Labs).	Cells	were	then	examined	
using	an	Axioscope	AI	microscope	(Zeiss)	
	
	
2.8	Chemical	Knockdowns	to	Silence	ERK	1	and	ERK	2	Using	Small	Interfering	RNA	
2.8.1	Cell	Plating	
	
	 Cells	were	plated	in	a	24-well	culture	dish	at	a	density	of	2.5x104	cells/well	in	0.5	
mls	culture	medium	without	antibiotics	and	incubated	at	37°C	and	5%	CO2	overnight.	
Each	knockdown	experiment	consisted	of	untreated	cells,	scrambled	siRNA,	ERK	1	siRNA	
(Santa	Cruz	Biotechnology	sc-29307),	ERK	2	siRNA	(Santa	Cruz	Biotechnology	sc-35335)	
and	a	combination	of	ERK	1	and	ERK	2.					
	
2.8.2	Transfection	
	
	 The	medium	was	changed	approximately	2	hours	before	transfection.	Both	
solution	A	(2µl	of	siRNA,	ERK	1,	ERK	2,	or	ERK	1/2	+	50	µl		IMEM	(no	serum,	no	
antibiotics)	and	solution	B	(2	µl		of	transfection	buffer	(Thermo	Scientific	DharmaFECT)	+	
50	µl	IMDM	(no	serum,	no	antibiotics))	were	made	and		left	for	15mins	at	room	
temperature.	They	were	then	mixed	and	left	for	15mins	at	room	temperature	before	
adding	100	µl	directly	to	each	appropriate	well.	
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Table	2.4:	Secondary	antibodies	used	in	immunocytochemistry	
Antibody	 Isotype	 Stock	
Concentration	
Concentration	 Source	
Alexafluor	555	
goat	anti-mouse	
A21127	
IgG1(γ1)	 2	mg/ml	 1/1000	 Life	Technologies	
Alexafluor	594	
goat	anti-mouse	
A21125	
IgG1(γ1)	 2	mg/ml	 1/1000	 Life	Technologies	
Alexafluor	555	
goat	anti-mouse	
A21137	
IgG2a	(γ2a)	 2	mg/ml	 1/1000	 Life	Technologies	
Alexafluor	488	
goat	anti-mouse	
A21131		
IgG2a	(γ2a)	 2	mg/ml	 1/1000	 Life	Technologies	
Alexafluor	555	
goat	anti-rabbit	
A21429	
IgG	(H+L)	 2	mg/ml	 1/1000	 Life	Technologies	
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Transfections	were	repeated	at	24	hours,	without	removing	any	media.	Protein	samples	
were	obtained	48-72	hours	after	first	transfection	by	using	RIPA	buffer	at	100	µl	per	
well.	Samples	were	stored	at	-80°C	until	Western	blot	analysis.	
		
2.9	Viability	Testing	Using	Crystal	Violet	Assay		
	
	 Cells	were	plated	in	a	96-well	plate	at	2x104	cells/well	and	incubated	overnight	at	
37°C	and	5%	CO2,	followed	by	replacement	of	media	containing	treatment	at	the	
appropriate	doses	using	three	replicate	wells	per	treatment	and	then	incubated	at	the	
desired	time.	Medium	was	then	aspirated	and	wells	were	washed	with	PBS.	Cell	viability	
was	tested	by	adding	100	µl	of	crystal	violet	(0.5%	crystal	violet	in	10%	neutral	buffered	
formalin	(VWR-EMD)	and	incubated	for	30mins	at	room	temperature.	After	which,	the	
crystal	violet	was	aspirated	and	the	plate	was	washed	under	the	tap	and	blotted	on	filter	
paper.	Plate	was	left	to	dry	for	5mins	at	room	temperature.	The	viable	cells,	represented	
by	remaining	crystal	violet,	were	detected	by	dissolving	it	in	100µl	of	30%	acetic	acid	in	
water.	The	plate	was	shaken	for	1min	and	the	absorbance	was	measured	on	an	ELISA	
reader	(Bio-Rad	model	3550)	at	595		nM.			
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Table	2.5:	Triple	negative	breast	cancer	cell	lines	and	mutations	
MDA-MB-231	 BT-20	 MDA-MB-468	 HS578T	 HS578Bst	
TNBC	epithelial	
cell	line	
WNT7B	
oncogene	
KRAS	(38G>A)	
&	BRAF	
(1391G>T)	
mutation	
Basal	B	
	
TNBC	epithelial	
cell	line	
PIK3CA	
(1616C>G)	
mutation	
Basal	A	
	
TNBC	epithelial	
cell	line	
PTEN	
(IVS4+1G>T)	
mutation	
Basal	A	
	
TNBC	
epithelial	
cell	line	
HRAS	
(35G>A)	
mutation	
Basal	B	
	
Normal	
mammary	
epithelial	
tissue	
	
	
	
Table	2.6:	Non-breast	cancer	cell	lines	and	mutations	
MDA-MB-435	 HT-29	
Metastatic	melanoma	
BRAF	mutation	V600E	
Colon	adenocarcinoma	
BRAF	mutation	
PIK3CA	mutation	
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Chapter	3:	Results	
	
Previous	research	in	the	Drover	laboratory	suggested	that	MAPK	activation	leads	
to	up-regulation	of	HLA	class	II	in	ERα_	breast	cancer	cell	lines.	Patients	with	ERα_	breast	
cancer	have	worse	prognoses	because	ERa-	tumors		are	resistant	to	hormonal	therapies	
and	frequently	over-express	growth	factor	receptors,	leading	to	activation	of	several	
downstream	signalling	pathways	such	as	NF-κB	and	MAPK	signaling.	
A	previous	student,	Ahmed	Mostafa,	found	inhibition	of	the	MEK	pathway	using	
U0126	(10	µM)	in	the	TNBC	line	MDA-MB-231c10A	resulted	in	significantly	decreased	
constitutive	and	IFN-γ	induced	HLA-DR	expression	on	the	cell	surface.	Ahmed	Mostafa	
also	confirmed	these	findings	in	VC5	and	MC2,	which	are	derived	from	the	parent	cell	
line,	MDA-231c10A.		Based	on	these	results,	it	was	hypothesized	that	the	MAPK	
signaling	is	important	for	HLA-DR	expression.		
To	further	explore	this	hypothesis,	Western	Blot	analysis	was	performed	on	
lysates	from	MDA-231c10A,	VC5	and	MC2	treated	or	not	with	U0126	followed	by	IFN-γ	
stimulation	or	not	for	24,	48	and	72	hours.	Contrary	to	the	extracellular	surface	flow	
results,	treatment	with	U0126	increased	intracellular	HLA-DR	expression	in	all	cell	lines	
at	all	time	points	examined.	These	contradictory	results	suggested	that	U0126	might	be	
having	an	effect	on	cellular	trafficking	or	recycling	of	the	HLA-DR	molecule.		
Since	MAPK	signaling	modulates	protein	stability	and	cell	surface	expression	of	
some	proteins75,78,88,	Ahmed	hypothesized	that	U0126	destabilizes	HLA-DR	molecules,	
which	might	help	explain	the	increase	of	HLA-DRα	at	the	expense	of	a	decrease	in	HLA-
DR	dimers.	Indeed,	immuncytochemistry	and	confocal	microscopy	revealed	that	U0126-
	 55	
treated	cells	showed	decreased	surface	HLA-DR	compared	to	DMSO,	with	considerable	
deposits	of	HLA-DR	localized	to	endocytic	vesicles.		
To	further	investigate	whether	the	effect	of	MEK	inhibition	on	HLA-DR	expression	
was	not	unique	to	U0126,	further	experiments	were	performed	using	different	MEKi	and	
other	breast	cancer	cell	lines	as	described	in	the	following	sections.			
	
3.1	U0126,	But	Not	PD98059	Decreases	Surface	HLA-DR	Expression	in	MDA-231c10A	
Cells	
To	confirm	and	expand	the	above	findings,	MDA-231c10A	cells	were	treated	with	
U0126	as	well	as	an	additional	MEKi,	PD98059,	to	see	if	the	effects	were	similar.	U0126	
and	PD98059	differ	in	their	inhibition	targets:	U0126	is	a	pan	MEK	inhibitor	whereas	
PD98059	is	specific	for	MEK	1.	Using	the	same	conditions	as	described	by	AM	(Ahmed	
PhD	thesis,	2014),	cells	were	plated	in	6-well	plates	at	2.5x105	cells/well	and	treated	
with	the	inhibitors	or	DMSO,	followed	by	stimulation	with	100units/ml	of	IFN-γ	1hr	after	
MEK	treatment.	At	72	hours	after	IFN-γ	stimulation,	cells	were	analyzed	for	surface	HLA-
DR	expression	by	flow	cytometry.	Western	blotting	for	pERK	was	conducted	on	lysates	
prepared	from	cells	treated	in	the	same	way	to	deduce	the	efficacy	of	the	inhibitors	
(Figure	3.1.	A).	While	flow	cytometry	results	confirmed	that	U0126	decreased	HLA-DR	
expression,	PD98059	had	only	a	marginal	effect	(Figure	3.1.	B).	This	was	not	due	to	drug	
inefficiency	since	PD98059	inhibited	pERK	to	the	similar	extent	to	U0126.		
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Figure	3.1:	MEK	inhibition	decreases	HLA-DR	expression.	
	
A)	Western	blot	of	whole	cell	lysates	from	MDA-231c10A	cells	(cultured	in	MEM)	treated	
with	U0126	(10	µM)	or	PD98059	(20	µM)	or	DMSO	(vehicle	control)	followed	by	IFN-γ	
(100	u/ml)	addition	1hr	after	MEKi	treatment.	Cells	were	then	incubated	for	a	total	
incubation	time	of	72	hours.	Western	blot	analysis	was	conducted	using	antibodies	
against	pERK	(Thr2202/Tyr204)	or	total	ERK	(K-23).	B)	Flow	cytometric	analysis	of	MDA-
231c10A	treated	with	U0126	(10	µM)	or	PD98059	(20	µM)	DMSO	(vehicle	control)	to	
determine	surface	HLA-DR	(L243)	expression.	Bar	graphs	represent	mean	fluorescence	
intensity	(MFI)	with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	
experiments.	Statistical	analysis	was	done	by	student	T-test	and	asterisks	represent	p	
value	<0.05.		
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3.2	U0126	and	PD98059	Differentially	Modulate	HLA	class	I	and	PD-L1	Expression		
	
We	expanded	our	findings	to	test	the	effects	of	MEKi(s)	on	another	antigen	
presentation	marker,	HLA	class	I.	HLA	Class	I	is	trafficked	to	the	cell	surface	through	a	
different	pathway	than	HLA-DR,	therefore	we	queried	if	U0126	would	have	the	same	
effect	on	its	expression.	Results	show	that	in	the	presence	of	INF-γ,	U0126	significantly	
decreases	surface	HLA	class	I	expression,	whereas	PD98059	does	not	(Figure	3.2.	A).		
After	observing	that	MEKi(s)	modulate	the	surface	expression	of	HLA	class	I	and	
HLA-DR,	we	questioned	whether	inhibition	has	effect	on	the	inhibitory	marker	PD-L1.	
Results	show	modest	decreases	in	PD-L1	expression	with	U0126	treatment,	although	not	
statistically	significant,	whereas	PD98059	increases	expression	significantly	(Figure	3.2.	
B)	
3.3	Effects	of	MEKi(s)	on	HLA-DR,	HLA	class	I	and	PD-L1	Expression	of	B-Cell	Line	SAVC	 	
Up	to	this	point,	experiments	were	conducted	on	MDA-231c10A.	Next,	we	tested	
to	see	if	these	effects	were	transferrable	to	an	APC	line,	more	specifically,	the	B	cell	line	
SAVC.	Cells	were	treated	as	above	with	U0126	(10	µM)	or	PD98059	(20	µM),	and	
incubated	for	72	hours	in	the	absence	of	IFN-γ.	As	an	APC,	SAVC	expresses	high	amounts	
of	HLA	class	I	and	HLA-DR	without	stimulation.	Three	independent	experiments	were	
done	and	results	showed	limited	effects	of	MEKi(s)	on	the	HLA	and/or	PD-L1	expression	
(Figure	3.3.	A,	B	&	C).	However,	U0126	does	decrease	in	HLA-DR	and	class	I.		Constitutive	
expression	of	PD-L1	was	too	low	to	deduce	any	trends.	
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Figure	3.2:	MEKi(s)	differently	modulate	HLA	class	I	and	PD-L1	expression.		
	
Flow	cytometric	analysis	of	MDA-231c10A	treated	with	U0126	(10	µM)	or	PD98059	(20	
µM)	DMSO	(vehicle	control)	in	the	presence	of	IFN-γ	to	determine	A)	surface	HLA	class	I	
(W6/32)	expression	and	B)	PD-L1	(MIH2)	expression.	Bar	graphs	represent	mean	MFI	
with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	experiments.	Statistical	
analysis	was	done	by	student	T-test	and	asterisks	represent	p	value	<0.05.		 	
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Figure	3.3:	MEKi(s)	have	no	significant	effect	on	HLA	and	PD-L1	expression	in	the	B-cell	
line,	SAVC.		
Flow	cytometric	analysis	of	SAVC	treated	with	U0126	(10	µM)	,		PD98059	(20	µM)	or	
DMSO	(vehicle	control)	to	determine	surface	HLA-DR	(L243)	expression	(A),	surface	HLA	
class	I	(W6/32)	expression	(B)	and		Surface	PD-L1	(MIH2)	expression	(C).	Bar	graphs	
represent	mean	MFI	with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	
experiments.	Statistical	analysis	was	done	by	student	T-test.		
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3.4	Viability	Assay	to	Determine	Dose	Responses	for	New	MEKi	
	
	 MEK	inhibitors	Sel,	Tram	and	PD0325901	were	evaluated	by	viability	assay	to	
determine	EC50	values.	MDA-231c10A	cells	were	plated	in	a	96-well	plate	and	treated	
with	three	concentrations	of	inhibitor	in	triplicate.	The	assay	was	conducted	according	
to	the	protocol	described	in	Materials	and	Methods,	Section	2.9,	using	concentrations	
similar	to	those	recommended	by	the	company	and	reported	in	the	literature	(Table	
3.1).		
3.4.1	Use	of	Clinically	Relevant	MEK	Inhibitors	Differentially	Affect	HLA-DR	Expression	in	
MDA-231c10A	Cells	
Since	our	initial	experiments	revealed	conflicting	results	with	U0126	and	
PD98059	on	HLA-DR,	HLA	class	I	and	PD-L1	expression,	we	added	three	additional	
MEKi(s):	Selumetinib	(Sel),	Trametinib	(Tram),	and	PD0325901.	PD0325901	and	Tram	are	
pan	MEK	inhibitors	like	U0126	whereas	Sel,	like	PD98059,	is	specific	for	MEK	1.	The	
efficacy	of	the	inhibitors	was	assessed	by	Western	blotting	(Figure	3.4.	A).	The	effects	of	
the	MEKi(s)	on	surface	HLA-DR	in	MDA-231c10A	cells	was	assessed	by	flow	cytometry	
(Figure	3.4.	B).	Cells	were	plated	in	6-well	plates	at	a	density	of	2.5x105	and	treated	with	
MEKi(s)	at	the	recommended	concentrations	of	15	nM,	2	nM	and	0.5	nM	for	Sel,	Tram	
and	PD0325901	respectively,	or	DMSO	and	stimulated	with	100	units	of	IFN-γ	1hr	after	
drug	treatment	and	then	incubated	for	a	total	of	72	hours.	All	three	inhibitors	have	
limited	effect(s)	on	surface	expression	of	HLA-DR.	
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Figure	3.4:	Analysis	of	MEK-meditated	effects	via	Western	blotting	and	flow	cytometry		
	
A)	Western	blot	of	whole	cell	lysates	from	MDA-231c10A	cells	(cultured	in	MEM)	treated	
with	Selumetinib	(15		nM),	Trametinib	(2		nM),	PD0325901	(0.5		nM),	or	DMSO	(vehicle	
control)	for	72	hours	and	then	with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment.		Blots	
were	probed	with	pERK	(Thr202/Tyr204)	or	alpha	tubulin	(B-7).	B)	Flow	cytometric	
analysis	of	MDA-231c10A	treated	with	Sel	(15		nM),	Tram	(2		nM),	&	PD0325901	(0.5		
nM),	or	DMSO	(vehicle	control)	for	72	hours	and	then	with	IFN-γ	(100	u/ml)	1hr	after	
MEKi	treatment	to	determine	surface	HLA-DR	(L243)	expression.	Bar	graphs	represent	
mean	MFI	with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	experiments.	
Statistical	analysis	was	done	by	student	T-test.	
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3.5	MEK	Inhibitors	Differentially	Modulate	Surface	HLA	class	I	and	PD-L1	Expression	in	
MDA-231c10A	Cells		
	
MDA-231c10A	cells	were	plated	and	treated	with	Sel	(15		nM),	Tram	(2		nM),	
PD0325901	(0.5		nM),	or	DMSO	and	stimulated	with	100	units	of	IFN-γ	for	72	hours.	
Surface	expression	of	HLA	class	I	was	assessed	by	flow	cytometry.	Sel,	and	Tram	show	
modest	increases	in	HLA	class	I	expression,	whereas	PD0325901	decreased	expression	
(Figure	3.5).	MDA-231c10A	does	not	constitutively	express	surface	PD-L1,	however,	IFN-
γ	can	increase	its	expression	.	No	MEKi(s)	significantly	modulated	surface	expression	of	
PD-L1	in	MDA-231c10A	treated	with	IFN-γ	(Figure	3.5.	B).		
	
3.6	The	Effects	of	ERK	Knockdowns	on	HLA	class	I	and	PD-L1	Surface	Expression	
	
Due	to	the	discrepancies	in	the	effects	the	MEK	inhibitors	have	on	HLA	and	PD-L1	
expression	on	the	MDA-231c10A	cell	line,	I	decided	to	use	siRNA	knockdown	of	ERK	1	
and	ERK	2.	ERK	knockdowns	were	achieved	by	transfection	of	ERK	1	and	ERK	2	siRNA	
three	times.	MDA-231c10A	cells	were	seeded	at	2.5x104	cells/well	in	a	24	well	plate.	
First	transfection	was	performed	at	24	hours	after	plating	cells	using	serum-free	and	
antibiotic-free	IMDM	media,	transfection	buffer	and	ERK	1	and	ERK	2	siRNA.		Second	and	
third	transfection	was	conducted	at	48	and	72	hours	after	plating	cells,	the	cells	were	
harvested	followed	by	analysis	using	flow	cytometry	and/or	Western	blotting.	
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Table	3.1:	EC50	values	of	inhibitors	as	determined	by	viability	assay		
Inhibitor	 Experimental	Value	
Selumetinib	 48	hours:	11	nM	
72	hours:	17.98	nM	
Trametinib	 48	hours:	0.64	nM	
72	hours:2.98	nM	
PD0325901	 48	hours:	28.62	nM	
72	hours:	0.8	nM	
	
	 	
	 68	
A.	
	
	
B.	
	 	
0
200
400
600
800
1000
1200
1400
1600
1800
2000
HLA	class	I
M
FI
DMSO+IFNY
Selemetinib(15nM)	+IFNY
Trametinib	(2nM)+IFNY
PD0325901(0.5nM)+IFNY
0
5
10
15
20
25
30
35
40
45
PD-L1
M
FI
DMSO+IFNY
Selemetininb(15nM)+IFNY
Trametinib(2nM)+IFNY
Pd0325901(0.5nM)+IFNY
	 69	
	
	
	
	
	
	
	
Figure	3.5:	Flow	cytometric	analysis	of	HLA	class	I	and	PD-L1	expression	in	MDA-231	
c10A.	
	Cells	were	treated	with	Selumetinib	(15		nM),	Trametinib	(2		nM),	PD0325901	(0.5		nM),	
or	DMSO	(vehicle	control)	and	induced	with	IFN-γ	(100	u/ml)	1hour	after	MEKi	
treatment	for	a	total	incubation	time	of	72	hours.			A)	Surface	HLA	class	I	(W6/32)	
expression,	and	B)	Surface	PD-L1	(MIH2)	expression	was	determined.	Bar	graphs	
represent	mean	MFI	with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	
experiments.	Statistical	analysis	was	done	by	student	T-test.	
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	siRNA	knockdowns	were	conducted	in	the	absence	of	IFN-γ,	therefore	HLA-DR	was	not	
examined	due	to	low	constitutive	expression.	The	results	show	modest	changes	in	class	I	
(Figure	3.6.	B)	and	PD-L1	expression	(Figure	3.6.	C),	but	the	differences	were	not	
significant	as	shown	by	flow	cytometry.	Western	blotting	analysis	confirmed	knockdown	
of	ERK	1	and	2	by	siRNA	(Figure	3.6.	A).	
	
3.7	Determining	the	Effect(s)	of	MEKi(s)	in	Additional	TNBC	Lines	
	
To	test	whether	the	effects	of	the	MEKi	(s)	on	HLA	and	PD-L1	expression	were	
cell	context	dependent,	we	expanded	the	panel	to	include	MDA-MB-231,	BT-20,	HS578T,	
and	MDA-MB-468.	Details	of	these	cell	lines	can	be	seen	in	Table	2.5	in	the	materials	
and	methods	section.	Both	MDA-MB-231	and	HS578T	have	a	RAS	mutation,	with	MDA-
MB-231	having	an	additional	BRAF	mutation.	BT-20	and	MDA-MB-468	have	PIK3CA	and	
PTEN	mutations	respectively.	Cells	were	plated	in	6-well	plates	at	a	density	of	2.5x105		
cells/well	and	treated	with	Sel,	Tram	or	U0126	at	10	µM,	10		nM	and	10	µM	respectively	
for	72	hours.	Drugs	were	used	at	higher	concentrations	due	to	updated	literature70.	We	
analyzed	MEKi–mediated	effects	on	constitutive	expression	levels	(left	panels	of	Figure	
3.7)	and	inducible	HLA-DR	through	stimulation	with	100	units	IFN-γ	(Figure	3.7	right	
panel).	The	results	are	depicted	as	an	overlay	histogram	representation	with	each	
coloured	line	matching	the	results	summarized	in	a	bar	graph.	
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Figure	3.6:	ERK	silenced	MDA-231c10A	cells	
	
A)	Western	blot	analysis	of	MDA-231c10A	cells.	ERK	1	&	2	were	silenced	(ERK	1	&	ERK	2	
siRNA)	or	not	(scrambled	siRNA)	in	MDA-231c10A	cells.	Whole	cell	lysates	were	
prepared	and	probed	for	total	ERK	(K-23)	with	alpha	tubulin	(B-7)	as	a	loading	control.	B)	
Flow	cytometry	analysis	of	surface	expression	of	HLA	class	I	(W6/32)	and	(C)	PD-L1	
(MIH2)	on	MDA-231c10A	cells	treated	with	or	without	ERK	siRNA	oligos.	Bar	graphs	
represent	mean	MFI	with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	
experiments.	Statistical	analysis	was	done	by	student	T-test.	
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	U0126	significantly	decreases	constitutive	HLA-DR	(Figure	3.7.	A	left	panel),	it	also	
decreases	induced	HLA-DR	expression,	but	not	significantly.		Neither	Sel	or	Tram	
significantly	affect	constitutive	or	induced	surface	HLA-DR	expression	in	MDA-MB-231.	
U0126	significantly	decreases	both	constitutive	and	induced	HLA-DR	expression	in	BT-20	
cells	as	shown	in	Figure	3.7.	B,	whereas	neither	Sel	or	Tram	significantly	impact	
constitutive	or	induced	HLA-DR	expression.	Little	effect	is	seen	with	any	inhibitors	in	
HS578T	cells	for	constitutive	or	induced	HLA-DR	expression	(Figure	3.7.	C).	Tram	
significantly	decreases	HLA-DR	expression	in	MDA	MB	468,	however	this	cell	line	has	
very	little	inducible	HLA-DR	expression	(Figure	3.10.	A).	Due	to	the	low	expression	of	HLA	
and	PD-L1	in	MDA-MB-468,	constitutive	expression	was	not	analyzed.		
The	MEKi	effects	on	constitutive	HLA	class	I	expression	in	MDA-MB-231,	BT-20,	
and	HS578T	cells	are	shown	on	the	left	side	panel(s)	in	Figure	3.8.	A,	B	and	C,	whereas	
the	inducible	effects	of	MEKi(s)	on	HLA	class	I	are	shown	on	the	right	side	panel(s)	in	
Figure	3.8.	A,	B	and	C,	respectively.	Constitutive	HLA	class	I	was	significantly	increased	in	
Sel-	and	Tram-treated	MDA-MB-231	cells,	whereas	U0126	treatment	resulted	in	
decreased	expression	(Figure	3.8.	A	left	panel).	Similarly,	Sel	and	Tram	treatment	
increased	inducible	HLA	class	I	in	MDA-MB-231	cells,	although	this	was	only	significant	
for	Tram-treatment.	By	contrast,	U0126	mediated	significantly	decreased	inducible	HLA	
class	I	expression.	For	constitutive	expression	in	BT-20	cells,	Tram	treatment	significantly	
increased	HLA	class	I	(Figure	3.8.	B	left	panel),	however	when	induced,	(Figure	3.8.	B	
right	panel),	HLA	class	I	was	significantly	reduced	by	U0126	treatment,	but	insignificantly	
increased	by	Sel	and	Tram.		MEKi(s)	show	limited	effects	on	HS578T	cells	(Figure	3.8.	C		
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Figure	3.7:	Analysis	of	HLA-DR	expression	in	MEKi-treated	TNBC	cells.	
Cells	were	treated	with	Selumetinib	(10	µM),	Trametinib	(10		nM),	U0126	(10	µM),	or	
DMSO	(vehicle	control)	in	absence	or	presence	of	IFN-γ	(100	U/ml),	added	1	hour	after	
MEKi(s),	for	a	total	incubation	of	72	hours.	Constitutive	(left	panels)	or	Induced	(right	
panels)	expression	of	surface	HLA-DR	(L243)	expression	in	A)	MDA-MB-231	cells	B)	BT-20	
cells	and	C)	HS578T	cells	were	determined	by	flow	cytometry.	Constitutive	expression	in	
HS578T	is	the	result	of	one	experiment.	Histogram	overlay	is	representative	of	one	
experiment.	In	overlays:	isotype	control,	DMSO	control,	sel,	tram	and	U0126.	Bar	graphs	
are	colour-matched	accordingly.	Bar	graphs	represent	mean	MFI	with	error	bars	+/-	SEM	
and	are	indicative	of	three	independent	experiments.	Asterisks	represent	p	value	<0.05	
(*)	and	<0.01	(**)	by	student	T-test.	
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Figure	3.8:	Analysis	of	HLA	class	I	expression	in	MEKi-treated	TNBC	cells.	
Cells	were	treated	with	Selumetinib	(10	µM),	Trametinib	(10	nM),	U0126	(10	µM),	or	
DMSO	(vehicle	control),	+/-	IFN-γ	(100	u/ml),	added	1	hr	after	MEKi(s)	for	a	total	
incubation	of	72	hours,	to	determine	constitutive	(left	panal)	or	induced	(right	panels)	of	
surface	HLA	class	I	(W6/32)	expression	in	A)	MDA-MB-231	cells	B)	BT-20	C)	HS578T	cells.	
Constitutive	expression	in	HS578T	is	the	result	of	one	experiment.	Histogram	overlay	is	
representative	of	one	experiment.	In	overlays:	isotype	control,	DMSO	control,	sel,	tram	
and	U0126.	Bar	graphs	are	colour-matched	accordingly.	Bar	graphs	represent	mean	MFI	
with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	experiments.	Asterisks	
represent	p	value	<0.05	(*)	and	<0.01	(**)	by	student	T-test.	
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left	and	right	panels).	In	contrast	to	the	other	cell	lines,	MDA-MB-468	significantly	
decreased	inducible	HLA	class	I	using	all	three	inhibitors	(Figure	3.10.	B).		
The	effects	of	the	MEKi(s)	on	constitutive	PD-L1	expression	in	MDA-MB-231,	BT-
20	and	HS578T	cells	are	shown	in	the	left	side	panel(s)	in	Figure	3.9.	A,	B	&	C,	
respectively.	U0126	treatment	significantly	decreased	constitutive	PD-L1	expression	in	
MDA-MB-231	cells,	while	both	Sel	and	Tram	somewhat	decreased	levels.	Tram	and	
U0126-treated	BT-20	cells	displayed	decreased	PD-L1,	but	the	effect	was	only	significant	
for	Tram-treated	cells	(Figure	3.9.	B	left	panel).	All	three	inhibitors	decreased	PD-L1	in	
IFN-γ	treated	MDA-MB-231	and	BT-20,	these	decreases	were	significant	for	U0126	while	
Tram	and	Sel	mediated	significant	decreases	in	MDA-MB-231	and	BT-20,	respectively	
(Figures	3.9.	A	&	B	right	panel(s)).	Interestingly,	MEKi(s)	have	limited	effects	on	both	
constitutive	and	induced	PD-L1	expression	in	HS578T	cells	(Figure	3.9.	C),	as	well	as	
induced	expression	in	MDA-MB-468	(Figure	3.10.	C).	These	results	suggest	that	although	
IFN-γ	stimulation	increases	levels	of	HLA	and	PD-L1,	the	effects	of	MEK	inhibition	are	
consistent	for	both	constitutive	and	induced	cells.		
	
3.10	Effects	of	MEKi(s)	on	HLA	and	PD-L1	Expression	in	Other	TNBC	Lines	as	Determined	
by	Western	Blotting	
	
Cells	plated	in	6-well	plates	at	a	density	of	2.5x105	cells/well	were	treated	with	
Sel,	Tram	or	U0126	for	72	hours.	Whole	cell	lysates	were	prepared	as	described	in	
section	2.6.1	and	subjected	to	Western	blot	analysis	using	antibodies	against	PD-L1,	HLA	
class	I,	pERK	and	total	ERK.	
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Figure	3.9:	Analysis	of	PD-L1	expression	in	MEKi-treated	TNBC.	
Cells	were	treated	with	Selumetinib	(10	µM),	Trametinib	(10	nM),	U0126	(10	µM),	or	
DMSO	(vehicle	control),	+/-	IFN-γ	(100	u/ml),	added	1	hr	after	MEKi(s),	for	a	total	
incubation	time	of	72	hours	to	determine	constitutive	(left	panels)	or	induced	(right	
panels)	to	determine	surface	PD-L1	(MIH2)	expression	in	A)	MDA-MB-231	cells	B)	BT-20	
cells	and	C)	HS578T	cells.	Constitutive	expression	in	HS578T	is	the	result	of	one	
experiment.	Histogram	overlay	is	representative	of	one	experiment.	In	overlays:	isotype	
control,	DMSO	control,	sel,	tram	and	U0126.	Bar	graphs	are	colour-matched	accordingly.	
Bar	graphs	represent	mean	MFI	with	error	bars	+/-	SEM	and	are	indicative	of	three	
independent	experiments.	Asterisks	represent	p	value	<0.05	(*)	and	<0.01	(**)	by	
student	T-test.	
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Figure	3.10:	Analysis	of	HLA	and	PD-L1	expression	in	MDA-MB-468	cells.	
Flow	cytometry	analysis	of	cells	that	were	treated	with	Selumetinib	(10	µM),	Trametinib	
(10	nM),	U0126	(10	µM),	or	DMSO	(vehicle	control)	and	induced	with	IFN-γ	(100	u/ml)	
1hr	after	MEKi	treatment,	and	incubated	for	72	hours	showing	mean	fluorescence	
intensity	(MFI)	of	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Histogram	overlay	is	representative	of	
one	experiment.	In	overlays:	isotype	control,	DMSO	control,	sel,	tram	and	U0126.	Bar	
graphs	are	colour-matched	accordingly.	Bar	graphs	represent	mean	MFI	with	error	bars	
+/-	SEM	and	are	indicative	of	three	independent	experiments.	Asterisks	represent	p	
value	<0.05	(*)	and	<0.01	(**)	by	student	T-test.	
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All	MEKi(s)	efficiently	inhibited	phosphorylation	of	ERK	at	72	hours	after	
treatment	in	MDA-MB-231	and	BT-20,	but	only	partially	in	HS578T	(Figure	3.11.	A,	B	&	
C).	At	72	hours,	both	MDA-MB-231	and	BT-20	show	decreased	expression	in	PD-L1	
through	treatment	with	all	three	MEKi(s).	The	effects	of	U0126	treatment	on	HLA	class	I	
expression	in	MDA-MB-231	and	BT-20	cells	as	seen	through	Western	blot	analysis,	do	
not	show	a	decrease	in	expression,	in	contrast	to	what	we	have	seen	in	flow	cytometry	
analysis.		
	Time	course	experiments	were	also	done	at	4,	24	and	48	hours	on	MDA-MB-231	
(Figure	3.12.	A)	and	MDA-MB-468	(Figure	3.12.	B)	to	determine	effects	of	time	on	
regulation	of	HLA	and	PD-L1	expression	by	MEKi(s).	The	results	of	the	time	course	show	
that	HLA	class	I	increased	from	4	to	48	hours	in	MDA-MB-231,	regardless	of	the	inhibitor	
used	(Figure	3.12.	A).	However,	both	Sel	and	Tram	treated	MDA-MB-231	cells	decrease	
PD-L1	levels	at	24	and	48	hours.	Although	in	Sel-treated	cells,	PD-L1	initially	increased	at	
4	hours	before	expression	decreased	as	incubation	continued.	In	MDA-MB-468	cells,	
HLA	class	I	increased	from	4	to	48	hours,	regardless	of	inhibitor	used,	however	PD-L1	
was	not	detected	(Figure	3.12.	B).	
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Figure	3.11:	Western	blot	analysis	of	whole	cell	lysates	from	MEKi-treated	MDA-MB-
231,	BT-20	and	HS578T	cells.	
	A)	MDA-MB-231;	B)	BT-20,	and	C)	HS578T	cells	treated	with	Selumetinib	(S)	(10	µM),	
Trametinib	(T)	(10	nM),	U0126	(10	µM)	or	DMSO	(vehicle	control	(C)),	and	induced	with	
IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	and	incubated	for	a	total	of	72	hours.		Blots	
were	probed	with	PD-L1	(E1L3N),	HLA	class	I	heavy	chain	(MUB2037P),	pERK	
(Thr202/Tyr204),	total	ERK	(K-23)	and	alpha	tubulin	(B-7).	Figure	is	a	representative	
chosen	out	of	3	experiments.			
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Figure	3.12:	Western	blot	analysis	of	whole	cell	lysates	from	MEKi-treated	MDA-MB-231	
and	MDA-MB-468	cells.	
A)	MDA-MB-231	cells		and	B)	MDA-MB-468	cells	treated	with	Selumetinib	(S)(10	µM),	
Trametinib	(T)	(10	nM),	U0126	(U)	(10	µM)	or	DMSO	(vehicle	control	(C))	and	treated	
with	with	100	u/ml	of	IFN-γ	1hr	after	MEKi(s).	Cells	were	incubated	for	4,	24	or	48	hours.	
Blots	were	probed	with	PD-L1	(E1L3N),	HLA	class	I	heavy	chain	(MUB2037P),	pERK	
(Thr202/Tyr204),	total	ERK	(K-23)	and	alpha	tubulin	(B-7).	Figure	is	a	representative	
chosen	out	of	3	experiments.			
	
	
	
	 	
	 88	
	
3.11	Effects	of	MEKi(s)	on	HLA	and	PD-L1	Expression	in	Non-Breast	Cancer	Lines	
	
The	next	question	we	asked	was	if	these	MEKi-effects	of	altered	HLA	and	PD-L1	
expression	are	unique	to	TNBC	lines.	We	chose	the	melanoma	line	MDA-MB-435	
because,	like	MDA-MB-231,	it	contains	a	BRAF	mutation.	The	BRAF	mutation	in	MDA-
MB-435	is	due	to	the	switching	of	a	valine	amino	acid	at	position	600	to	a	glutamic	
acid87.	We	also	chose	the	colon	cancer	line	HT-29,	as	it	also	contains	a	BRAF	mutation87.	
We	set	up	both	constitutive	and	IFN-γ	induced	experiments	and	assessed	via	flow	
cytometry	to	determine	the	effects	of	inhibition	on	surface	HLA	and	PD-L1	expression.		
U0126	significantly	decreases	constitutive	(left	panel)	and	induced	(right	panel)	
HLA-DR	expression	in	MDA-MB-435	(Figure	3.13.	A).	There	are	no	significant	effects	of	
the	MEKi(s)	on	induced	HLA-DR	expression	(right	panel)	in	HT-29,	whereas	the	
expression	of	constitutive	HLA-DR	(left	panel)	was	too	low	to	see	any	effect	(Figure	3.13.	
B).		
U0126	treated	MDA-MB-435	cells	show	significant	decreases	in	constitutive	HLA	
class	I	(Figure	3.14.	A	left	panel),	whereas	there	are	no	significant	effects	seen	in	the	
induced	cells.	However,	both	Sel	and	Tram	show	modest	increases	in	both	constitutive	
and	induced	expression	(Figure	3.14.	A).	There	are	no	significant	MEKi-mediated	effects	
seen	in	either	constitutive	(Figure	3.14.	B	left	panel)	or	induced	(right	panel)	expression.		
Constitutive	expression	of	PD-L1	was	significantly	reduced	in	MDA-MB-435	when	
treated	with	U0126	(Figure	3.15.	A	left	panel)	while	induced	expression	of	PL-D1	was	
significantly	reduced	by	Tram	(Figure	3.15.	right	panel).	However,	all	three	inhibitors	in	
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Figure	3.13:	Analysis	of	HLA-DR	expression	in	MDA-MB-435	and	HT-29	cells.	
Cells	were	treated	with	Selumetinib	(10	µM),	Trametinib	(10	nM),	U0126	(10	µM),	or	
DMSO	(vehicle	control),	followed	by	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	for	
induced	expression	(right	panel),	or	none,	for	constitutive	expression	(left	panel).	Cells	
were	incubated	for	a	total	of	72	hours.	Flow	cytometry	analysis	shows	surface	HLA-DR	
(L243)	expression	in	A)	MDA-MB-435	cells	and	B)	HT-29	cells.	Histogram	overlay	is	
representative	of	one	experiment.	In	overlays:	isotype	control,	DMSO	control,	sel,	tram	
and	U0126.	Bar	graphs	are	colour-matched	accordingly.	Bar	graphs	represent	mean	MFI	
with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	experiments.	Asterisks	
represent	p	value	<0.05	(*)	and	<0.01	(**)	by	student	T-test.	
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	both	constitutive	and	induced	experiments	show	decreases	in	PD-L1	expression.	
As	was	the	case	for	HLA	class	I	expression,	no	obvious	MEKi-mediated	effects	are	seen	in	
either	constitutive	(3.15	left	panel)	or	induced	(right	panel)	HT-29	cells.	
	
3.12	Effects	of	MEKi(s)	on	HLA	and	PD-L1	Expression	in	MDA-MB-435	and	HT-29	as	
Determined	by	Western	Blotting	
MDA-MB-435	and	HT-29	cells	were	plated	at	2.5x105	cells/well	and	treated	with	
Sel	(10	µM),	Tram	(10	nM),	U0126	(10	µM),	or	DMSO	as	control	and	induced	with	100	u	
of	IFN-γ	for	4,	24	and	48	hours.	All	three	MEKi(s)	inhibited	phosphorylated	ERK	and	
markedly	decreased	inducible	PD-L1	expression	in	IFN-γ	treated	MDA-435	cells	(Figure	
3.16.	A).	HLA	class	I	expression	was	not	detectable	at	4	hours,	but	increases	at	24	and	
48hr	time	point.	Figure	3.16.	B	shows	both	induced	and	constitutive	expression	at	48hr	
time	point.	MDA-MB-435	cells	have	constitutive	ERK	expression,	but	little	HLA	class	I	
heavy	chain	is	seen.	PD-L1	is	not	shown	as	there	was	too	little	constitutive	expression.	
To	confirm	the	results	in	Figure	3.16,	I	conducted	additional	experiments	with	
another	time	point	at	72	hours	after	MEKi	treatment.	In	MDA-MB-435,	clear	increases	in	
HLA	class	I	are	seen	in	lanes	treated	with	inhibitors.	Decreases	in	PD-L1	expression	are	
also	seen	in	inhibitor-treated	lanes.	(Figure	3.17.	A).	The	effects	of	MEK	inhibition	on	HT-
29	cells	show	clear	decreases	in	pERK	in	treated	lanes	(Figure	3.17.	B),	but	little	
difference	is	seen	in	HLA	class	I	heavy	chain	expression.		There	was	no	PD-L1	detected	in	
HT-29	cells.		
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Figure	3.14:	Analysis	of	HLA	class	I	expression	in	MDA-MB-435	and	HT-29	cells.	
Cells	were	treated	with	Selumetinib	(10	µM),	Trametinib	(10	nM),	U0126	(10	µM),	or	
DMSO	(vehicle	control),	with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	for	induced	
expression	(right	panel),	or	none,	for	constitutive	expression	(left	panel).	Cells	were	
incubated	for	a	total	of	72	hours.	Flow	cytometric	analysis	shows.	Surface	HLA	class	I	
(W6/32)	expression	for	A)	MDA-MB-435	cells	and	B)	HT-20	cells.	Histogram	overlay	is	
representative	of	one	experiment.	In	overlays:	isotype	control,	DMSO	control,	sel,	tram	
and	U0126.	Bar	graphs	are	colour-matched	accordingly.	Bar	graphs	represent	mean	MFI	
with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	experiments.	Asterisks	
represent	p	value	<0.05	(*)	and	<0.01	(**)	by	student	T-test.	
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Figure	3.15:	Analysis	of	PD-L1	expression	in	MDA-MB-435	and	HT-29	cells.	
Cells	were	treated	with	Selumetinib	(10	µM),	Trametinib	(10	nM),	U0126	(10	µM),	or	
DMSO	(vehicle	control),	with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	for	induced	
expression	(right	panel),	or	none,	for	constitutive	expression	(left	panel).	Cells	were	
incubated	for	a	total	of	72	hours.	Flow	cytomtryic	analysis	shows	surface	PD-L1	(MIH2)	
expression	for	A)	MDA-MB-435	cells	and	B)	HT-20	cells.	Histogram	overlay	is	
representative	of	one	experiment.	In	overlays:	isotype	control,	DMSO	control,	sel,	tram	
and	U0126.	Bar	graphs	are	colour-matched	accordingly.	Bar	graphs	represent	mean	MFI	
with	error	bars	+/-	SEM	and	are	indicative	of	three	independent	experiments.	Asterisks	
represent	p	value	<0.05	(*)	and	<0.01	(**)	by	student	T-test.	
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Figure	3.16:	Western	blot	of	whole	cell	lysates	from	time	response	of	MDA-MB-435	
cells.	
Cells	were	treated	with	Selumetinib	(S)	(10	µM),	Trametinib	(T)	(10	nM),	U0126	(U)	(10	
µM)	or	DMSO	(vehicle	control	(C))	and	induced	or	not	with	IFN-γ	(100	u/ml)	1hr	after	
MEKi	treatment.	A)	MEKi-treated	induced	MDA-MB-435	cells	for	4,	24	and	48hr	time	
points	and	B)	MEKi-treated	induced	and	constitutive	MDA-MB-435	cells	for	48	hours.	
Blots	were	probed	with	PD-L1	(E1L3N),	HLA	class	I	heavy	chain	(MUB2037P),	pERK	
(Thr202/Tyr204),	total	ERK	(K-23)	and	alpha	tubulin	(B-7).	Figure	is	a	representative	
chosen	out	of	3	experiments.			
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Figure	3.17:	Western	blot	data	of	whole	cell	lysates	from	MEKi-treated	MDA-MB-435	
and	HT-29	cells.	
Cells	were	treated	with	Selumetinib	(S)	(10	µM),	Trametinib	(T)	(10	nM),	U0126	(U)	(10	
µM)	or	DMSO	(vehicle	control	(C))	and	induced	with	IFN-γ	(100	u/ml)	1hr	after	MEKi	
treatment	for	a	total	incubation	time	of	72	hours.	Western	blot	analysis	of	MEKi-treated	
A)	MDA-MB-435	and	B)	HT-29	cells.		Blots	were	probed	with	PD-L1	(E1L3N),	HLA	class	I	
heavy	chain	(MUB2037P),	pERK	(Thr202/Tyr204),	total	ERK	(K-23)	and	GAPDH	(AB8245).	
Figure	is	a	representative	chosen	out	of	3	experiments.			
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3.13	Effects	of	MEKi(s)	on	HLA	class	I	and	PD-L1	Expression	in	MDA-MB-435	cells	as	
Determined	by	Immunofluorescence	
	
	 After	obtaining	results	through	flow	cytometry	and	Western	blotting,	we	then	
treated	MDA-MB-435	cells	with	MEKi(s)	and	analyzed	via	immunofluorescence.	Cells	
were	plated	in	8-well	chamber	slides	and	treated	with	U0126	(10	µM),	Selumetinib	(10	
µM)	or	Trametinib	(10	nM)	and	incubated	for	72	hours.	Cells	were	fixed	and	stained	for	
HLA	class	I	and	PD-L1	and	analyzed	on	a	Zeiss	Axiovision	immunofluorescence	
microscope.		
When	treated	with	Tram,	there	appears	to	be	a	higher	intensity	of	HLA	class	I	
expression	while	simultaneously	decreasing	intensity	of	PD-L1	(Figure	3.18),	confirming	
the	results	observed	in	flow	cytometry	analysis	(Figure	3.14	and	3.15)	and	Western	blot	
analysis	(Figure	3.17)	
	
3.14:	U0126	Down-regulates	Surface	HLA	and	PD-L1	Expression	Consistently	Across	all	
Cell	Lines	Tested.	
	 After	the	previous	flow	cytometry	experiments	have	shown	that	treatment	with	
U0126	consistently	decreased	surface	HLA-DR,	HLA	class	I	and	PD-L1	expression	
regardless	of	the	cell	line	used,	a	separate	statistical	analysis	was	used	to	compare	the	
effects	of	each	inhibitor	to	one	another	(chapter	2.5.2).	Results	shown	in	Figure	3.19	
show	that	U0126-treatment	decreased	surface	HLA-DR	expression,	and	its	effect	are	
significantly	different	compared	to	Sel	(Figure	3.19.	A).			 	
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Figure	3.18:	Trametinib	treated	cells	show	increases	in	HLA	class	I	expression	and	
decreases	in	PD-L1	expression.		
Immunofluoresence	of	MDA-MB-435	cells	treated	for	72	hours	with	DMSO	or	
Trametinib	(10	nM)	in	the	presence	of	100	units	IFN-γ.	Cells	were	methanol	
permeabilized	and	paraformaldehyde	fixed,	and	stained	with	primary	antibodies	HLA-DR	
(L243),	HLA	class	I	(w6/32)	and	PD-L1	(E1L3N)	and	then	with	Alexa	Fluor	488	G2A	and	
Alexa	Fluor	555	IgG1	as	secondary	antibodies	with	DAPI	as	blue	nuclear	stain.	
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The	effects	of	U0126	treatment	on	HLA	class	I	are	also	significantly	different	than	
both	Sel	and	Tram	(Figure	3.19.	B),	as	well	as	significantly	different	compared	to	Tram	in	
regards	to	PD-L1	expression	(Figure	3.19.	C).	These	results	show	that	U0126	is	unique	in	
its	effects	on	HLA	and	PD-L1	regulation	as	compared	to	Sel	and	Tram.	
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Figure	3.19:	U0126	modulates	HLA	and	PD-L1	differently	than	other	MEKi(S)	in	all	cell	
lines.	
Compilation	of	MEK-mediated	effects	of	U0126	(10	µM),	Selumetinb	(10	µM)	and	
Trametinib(10	nM)	treatment	in	100u/ml	IFN-γ	induced	MDA-MB-231,	BT-20,	MDA-MB-
468,	MDA-MB-435,	HS578T,	and	HT-29	cells	as	analyzed	by	flow	cytometry	to	
determine:	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Statistical	analysis	was	done	by	Anova	
and	Tukey	HSD	test.	Bar	graphs	represent	mean	MFI.	Asterisks	represent	significance	of	
p	value	<0.05	(*)	and	<0.01	(**).	
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Chapter	4:	Discussion		
	
4.1	Results	Summary	
In	the	course	of	this	research,	we	demonstrated	that	the	MAPK	pathway	plays	a	
role	in	the	regulation	of	the	antigen	presenting	molecules	HLA-DR	and	HLA	class	I,	as	
well	as	the	inhibitory	molecule	PD-L1.	Through	the	use	of	several	MEK	inhibitors	we	
have	shown	that	these	drugs	differentially	affect	HLA	and	PD-L1	expression.	We	
confirmed	previous	research	in	the	Drover	laboratory,	that	U0126-treated	MDA-
231c10A	cells	significantly	decreased	surface	HLA-DR	expression77.	Furthermore,	this	
down-regulation	was	observed	in	other	TNBC	lines:	MDA-MB-231,	BT-20,	MDA-MB-468	
as	well	as	in	the	melanoma	line,	MDA-MB-435,	indicating	that	the	effect	was	not	cell-
context	dependent.		
Due	to	the	differential	effects	of	U0126	and	PD98059	treatment	on	HLA-DR	
expression	in	MDA-231c10A	cells,	we	questioned	what	effects	they	would	have	on	HLA	
class	I,	which	traffics	through	the	endogenous	pathway	(Figure	1.3).	Furthermore	this	
was	of	clinical	relevance	since	HLA	class	I	is	frequently	down-regulated	on	tumor	cells	
thereby	contributing	to	immune	evasion	of	the	tumour26.	We	found	that	U0126	also	
down-regulated	HLA	class	I	and	PD-L1	expression	in	MDA-231c10A	as	well	as	other	TNBC	
and	non-TNBC	lines	showing	a	stark	contrast	in	its	effects	on	HLA	and	PD-L1	modulation	
compared	to	the	other	inhibitors	as	confirmed	in	Figure	3.19.	
Clinically	relevant	MEK	inhibitors	Selumetinib	and	Trametinib	generally	increased	
HLA	class	I	and	decreased	PD-L1	expression	in	the	majority	of	cell	lines	tested	as	
assessed	by	flow	cytometry	and	immunofluorescence,	however	their	effects	on	HLA-DR	
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varied.	Western	blotting	showed	increased	HLA	class	I	intracellularly	even	in	U0126-
treated	samples,	whereas	PD-L1	protein	levels	were	decreased	in	all	cell	lines	tested	that	
showed	sensitivity	to	MEK-inhibition.		
The	effects	of	MEKi(s)	on	HLA	and	PD-L1	expression	were	consistent	in	the	cell	
lines	used	in	this	research,	with	Sel	and	Tram	generally	increasing	surface	HLA	class	I	and	
decreasing	PD-L1.	In	contrast,	U0126-mediated	effects	are	significantly	different	from	
the	others.	The	mechanism(s)	in	which	these	inhibitors	modulate	expression	needs	to	be	
addressed.		
			
4.2	MEKi-mediated	Effects	on	MDA-231c10A	
The	effects	of	MEK	inhibition	in	MDA-231c10A	differ	slightly	from	the	parent	line	
MDA-MB-231,	For	example,	although	U0126	decreased	HLA-DR,	HLA	class	I	and	PD-L1	in	
both	lines,	the	effect	on	HLA-DR	was	significant	for	c10A,	while	the	effect	on	HLA	class	I	
and	PD-L1	was	more	pronounced	in	MDA-MB-231.	Similarly,	Sel	and	Tram	treatment	
increased	HLA	class	I	and	decreased	PD-L1	in	both	lines,	but	the	effects	were	only	
significant	for	MDA-MB-231.	These	differential	effects	of	the	inhibitors	are	not	due	to	
technical	issues,	as	we	demonstrated	using	Western	blotting	that	all	inhibitors	
successfully	inhibited	phosphorylated	ERK	(Figure	3.1.	A	and	Figure	3.4.	A).	Due	to	these	
variations,	we	took	a	closer	look	at	the	differences	between	both	lines.		
MDA-231c10A	is	grown	in	estrogen-depleted	medium	and	differs	from	the	
parent	line	by	lacking	ERβ.	Although	previous	research	in	the	Drover	laboratory	showed	
that	estradiol	had	little	effect	on	HLA-DR	expression	in	U0126-treated	MDA-231c10A	
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cells77,	I	performed	a	preliminary	experiment	to	explore	whether	estradiol	altered	the	
effects	of	Sel	and	Tram	on	HLA	and	PD-L1	expression	in	c10A	cells	(Appendices		1	and	2).	
We	observed	limited	effects	of	estradiol	on	HLA	and	PD-L1	expression	in	MDA-231c10A	
cells,	however,	when	used	in	combination	with	either	Sel	or	Tram	the	effects	on	HLA	
class	I	and	HLA-DR	were	slightly	diminished.	While	no	differences	were	seen	in	PD-L1	
expression.	As	this	experiment	was	done	once,	it	is	hard	to	draw	any	conclusions,	
however	these	results	support	the	theory	that	both	Sel	and	Tram	alter	HLA	and	PD-L1	
expression	through	different	mechanisms,	which	could	help	explain	why	estradiol	
diminishes	inhibitor-mediated	effects	on	HLA	but	not	PD-L1.		
Although	Sel	and	PD98059	are	MEK	1-specific,	Sel	had	the	opposite	effect	as	PD-
L1	was	decreased	in	Sel-treated	MDA-231c10A	cells,	but	increased	with	PD98059	
treatment.	Similarly,	the	effects	on	HLA	and	PD-L1	by	the	pan	MEK	inhibitors,	Tram	and	
PD0325901,	were	not	analogous	to	those	mediated	by	U0126.	For	example,	Tram,	unlike	
U0126,	increased	HLA	class	I,	but	like	U0126	it	decreased	PD-L1	expression.	PD0325901	
has	almost	no	effect	on	HLA	and	PD-L1.	Because	of	these	variations,	we	queried	if	the	
mechanisms	employed	by	these	inhibitors	were	similar	for	some	molecules,	such	as	PD-
L1,	yet	varied	for	others	(HLA).	This	also	suggested	to	us	that	the	effects	of	the	MEKi(s)	
may	not	be	specifically	MEK	1-	or	MEK	2-dependent.	
It	is	currently	unclear	why	U0126	significantly	differs	from	the	other	MEKi(s)	in	its	
effects	on	HLA	and	PD-L1	modulation.	Although	a	pan	MEK	inhibitor,	the	reason	for	
differential	effects	might	be	seen	further	downstream	than	MEK	1/2.	As	ERK	1/2	are	the	
only	downstream	targets	of	MEK	activation	and	are	last	in	the	MAPK	pathway	(Chapter	
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1.5),	it	was	anticipated	that	by	knocking	down	ERK	1	and	ERK	2	using	small	interfering	
RNA,	we	might	better	understand	the	differential	effects	of	the	inhibitors.	Due	to	MDA-
231c10A	showing	moderate	levels	of	both	constitutive	HLA	class	I	and	PD-L1,	the	
experiments	were	done	in	the	absence	of	IFN-γ.	As	the	results	of	the	knockdowns	
compared	to	the	scrambled	control	siRNA,	were	not	significant,	we	determined	that	the	
inhibitor	mediated	effects	were	not	due	to	ERK	inactivation.	Furthermore,	it	would	have	
been	more	relevant	to	have	used	MEK-specific	siRNA	as	the	inhibitors	are	MEK-,	not	
ERK-specific	and	their	effects	might	only	be	induced	at	that	particular	point	in	the	MAPK	
pathway.	
	
4.3	MEKi-mediated	Effects	on	Other	TNBC	Lines	
To	determine	whether	the	effects	of	MEKi(s)	on	HLA	and	PD-L1	in	MDA-231c10a,	
were	specific	for	TNBC,	we	performed	the	same	treatments	and	experiments	on	four	
additional	TNBC	lines.	If	the	effects	of	MEKi(s)	were	similar	in	other	lines	it	would	help	
determine	mechanistically	the	reason	for	altered	expression	of	HLA	and	PD-L1.	The	
mutations	in	each	cell	line	varies,	as	shown	in	Table	2.5:	MDA-MB-231	has	both	KRAS	
and	BRAF	mutations,	BT-20	has	a	PIK3CA	mutation,	MDA-MB-468	has	a	PTEN	mutation,	
and	HS578T	has	a	HRAS	mutation.	Tumours	that	carry	BRAF	mutations	have	been	shown	
to	be	more	sensitive	to	Sel	and	Tram83,89,90,91.	Due	to	the	BRAF	mutation	expressed	in	
MDA-MB-231,	we	hypothesized	that	Sel	and	Tram	would	have	similar	effects	on	HLA-DR	
expression	in	all	cell	lines	that	contained	this	mutation.	However,	we	found	that	the	
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effects	varied	among	the	cell	lines	with	BRAF	mutations,	whereas	U0126	consistently	
decreased	surface	expression.		
Both	Sel	and	Tram	increased	constitutive	and	induced	surface	HLA	class	I	
expression	in	MDA-MB-231	and	BT-20	despite	differences	in	mutations,	whereas	both	
had	no	effects	on	HLA	class	I	expression	in	HS578T.	The	limited	efficacy	in	HS578T	may	
be	due	to	a	high	threshold	in	this	cell	line	for	these	drugs,	as	some	cell	lines	require	
higher	concentrations.	This	was	shown	in	a	paper	by	Loi	and	colleagues	(2015)	that	large	
concentrations	of	Trametinib	were	needed	to	inhibit	phosphorylated	ERK	in	the	mouse	
tumor	lines	AT3ova	and	4T18.	This	potentially	high	threshold	for	Sel	or	Tram-mediated	
effects	on	HLA	class	I	in	HS578T	appeared	to	be	consistent	with	Western	blot	analysis,	
showing	that	lanes	with	Sel	and	Tram	incompletely	inactivated	phosphorylated	ERK	at	
the	72hr	time	point.		
The	effects	of	MEKi(s)	on	MDA-MB-468	show	stark	contrasts,	as	it	was	the	only	
cell	line	to	show	decreased	HLA	class	I	expression	with	inhibitor	treatment	other	than	
U0126.	Explanations	for	this	could	be	its	PTEN	mutation,	which	could	impact	the	
inhibitor-mediated	effects	as	links	between	the	loss	or	mutation	in	PTEN	and	the	
induction	of	PD-L1	has	been	reported	in	prostate	cancer	cells50,54.	A	future	direction	
would	be	to	explore	the	effects	of	PI3K	pathway	inhibition	on	HLA	and	PD-L1	expression	
in	MDA-MB-468	cells.		
In	MDA-MB-231	and	BT-20,	Sel,	Tram	and	U0126	decreased	both	constitutive	
and	induced	surface	PD-L1	and	protein	levels	seen	in	Western	blots.	Despite	different	
mutations,	both	cell	lines	have	similar	responses	to	the	inhibitors.	Western	blots	are	
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consistent	with	flow	cytometric	analysis,	which	indicates	the	inhibitors	are	decreasing	
both	surface	and	intracellular	protein	levels.	This	suggests	the	inhibitors	are	not	trapping	
PD-L1	intracellularly	as	may	be	the	case	with	HLA.		
		
4.4	MEKi-mediated	Effects	on	Non-BC	Lines	
To	determine	if	the	MEKi-mediated	effects	on	HLA	and	PD-L1	expression	were	
common	to	cancers	other	than	breast,	we	included	two	lines,	MDA-MB-435	and	HT-29,	
which	also	have	dysregulated	MAPK	pathways.	MDA-MB-435	has	a	BRAF	mutation,	and	
despite	some	confusion	in	the	literature	as	to	the	source	from	which	this	line	was	
originally	derived,	it	is	now	commonly	accepted	as	a	melanoma	line87.	HT-29	is	an	
adenocarcinoma	colon	cancer	line	also	containing	a	BRAF	mutation87.	
		 In	MDA-MB-435,	U0126	consistently	decreased	surface	HLA-DR,	HLA	class	I	and	
PD-L1	expression,	whereas	Sel	and	Tram	both	increased	HLA	class	I	expression	and	
decreased	PD-L1	as	was	seen	in	MDA-MB-231	and	BT-20.	The	effects	on	MDA-MB-435	
are	seen	in	both	constitutively	and	IFN-γ	induced	cells.	In	HT-29,	MEK	inhibition	with	Sel	
and	Tram	similarly	increased	HLA	class	I	and	decreased	PD-L1	expression.	Western	
blotting	analysis	on	these	lines	confirmed	results	seen	from	flow	cytometry	with	a	
decrease	in	PD-L1	expression	at	the	protein	level.	Interestingly,	as	was	the	case	with	the	
BC	lines,	HLA	class	I	protein	was	not	diminished	with	U0126	treatment,	despite	being	
decreased	on	the	surface.	The	increase	in	protein	HLA	class	I	in	cell	lines	treated	with	
both	Sel	and	Tram	are	consistent	with	surface	expression	via	flow	cytometry.	This	effect	
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is	not	novel,	and	it	has	been	documented	in	the	literature,	however	mechanisms	
regarding	altered	expression	are	still	unknown8.	
	
4.5	Mechanisms	
The	mechanism	through	which	U0126	down-regulates	HLA-DR	has	not	been	fully	
elucidated,	however,	in	previous	Western	blot	and	immunofluorescence	analysis	of	
MDA-231c10A	cells,	intracellular	levels	of	HLA-DR	were	not	decreased,	nor	were	they	
reduced	at	transcriptional	levels	as	shown	by	RT-PCR77.	Decreased	surface	HLA-DR	
expression	despite	abundant	levels	of	intracellular	HLA-DR	proteins	could	be	due	to		
disruption	in	trafficking	or	recycling	where	U0126,	either	through	a	MEK-dependent	or	
off-target	mechanism,	mediates	trapping	of	HLA-DR	in	endosomal	vesicles92.	To	further	
explore	this	potential	mechanism,	additional	immunofluorescence	analyses	using	
markers	for	HLA-DR	and	specific	endosomes	were	performed,	but	did	not	allow	any	
clear	conclusions	(data	not	shown).	Complicating	this	further	was	our	finding	that	
additional	MEK	inhibitors	had	variable	effect(s)	on	HLA-DR	in	all	cells,	regardless	of	MEK-
specific	targets.	These	data	indicate	that	mechanistically,	U0126	modulates	HLA-DR	
expression	differently	than	the	others.	
HLA	class	I	down-regulation	in	U0126-treated	cells	is	not	novel;	Robertson	and	
colleagues	(2006)	showed	U0126-mediated	decreased	surface	HLA	class	I	expression	in	
HeLa	cells,	however	increased	intracellular	pools	of	“trapped”	HLA	was	seen	in	the	
treated	cells92.	As	U0126	shows	similar	effects	of	down-regulation	of	both	HLA-DR	and	
HLA	class	I,	it	hints	that	the	mechanism	employed	for	down-regulation	is	similar	for	both	
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molecules	with	our	results	reinforcing	the	potential	trafficking	mechanism	employed	by	
U012677,92.	Since	the	start	of	this	thesis	project,	the	increase	in	surface	levels	of	HLA	
class	I	through	treatment	with	Sel	and	Tram	has	been	documented	in	the	literature,	with	
Loi	and	colleagues	(2015)	showing	that	treatment	with	Sel	and	Tram	greatly	increased	
constitutive	and	induced	surface	HLA	class	I	expression	in	mouse	model	lines	of	breast	
cancer8,	whereas	Liu	et	al	(2015)	showed	increases	through	treatment	with	both	Tram	
alone	or	in	combination	with	the	BRAF	inhibitor	Dabrafinib	in	human	melanoma	lines93.	
Liu	and	colleagues	found	this	increase	was	associated	with	increases	in	apoptotic	
markers	as	well	as	down-regulation	of	immunosuppression	factors.	Additionally,	Hu-
Lieskovan	and	colleagues	(2015)	also	saw	increases	in	HLA	class	I	through	MEK	inhibition	
with	Tram	treatment	in	a	mouse	BRAF	V600E	melanoma	model94.	Due	to	the	general	
agreement	that	down-regulation	of	HLA	class	I	leads	to	poorer	prognosis	and	tumor	
escape26,95,	these	results	indicate	increased	chance	of	tumor	destruction	and	decreased	
growth	via	treatment	with	MEK	inhibitors.	Incidentally,	when	observing	micro	dissected	
tumour	regions,	Garrido	and	colleagues	(2012)	showed	that	high	levels	of	HLA	class	I	
gene	expression	could	be	observed	in	regression	but	not	in	progressing	metastasis95.	
This	finding	supports	that	modulations	in	HLA	class	I	on	tumour	cells	could	have	
therapeutic	effects96.	Since	hyperactivation	of	MAPK	allows	cells	to	proliferate	
uncontrollably,	it	may	be	that	negative	regulation	of	HLA	class	I	could	be	a	mechanism	
employed	by	MAPK	pathway-mutated	tumor	cells	to	escape	immune	surveillance.	
Therefore,	by	inhibiting	the	pathway,	HLA	class	I	expression	is	restored.	
	 114	
The	mechanism	by	which	MAPK	regulates	PD-L1	is	not	fully	understood.	
However,	PD-L1	is	transcriptionally	regulated	by	the	c-jun	protein47,	consequently	U0126	
works	by	functionally	antagonizing	AP-1	transcriptional	activity,	which	is	formed	by	c-jun	
and	c-fos70.	Therefore	U0126	may	interfere	with	PD-L1	at	the	transcriptional	level,	which	
is	supported	by	the	decreases	in	PD-L1	protein	levels	seen	in	Western	blots	of	whole	cell	
lysates	(WCL)	prepared	from	all	cell	lines	in	which	the	MEKi(s)	successfully	inhibited	
phosphorylated	ERK.	Decreases	in	transcriptional	PD-L1	activity	via	MEK	inhibition	has	
been	documented,	with	a	study	confirming	both	decreased	PD-L1	and	increased	HLA	
class	I	and	II	in	the	melanoma	lines	A375	and	sk-MEL-24	via	RT-PCR	and	flow93.		As	these	
decreases	in	PD-L1	are	also	observed	with	both	Sel	and	Tram	treatment,	the	mechanism	
for	decreased	expression	may	be	common	to	all	three	inhibitors.	However,	the	effects	of	
MEK	inhibition	on	PD-L1	expression	are	controversial	in	the	literature	with	some	articles	
citing	decreases	in	expression,	while	others	cite	large	increases.	Liu	et	al	(2015)	found	
treatment	with	Tram	decreased	surface	PD-L1	levels	in	human	melanoma	lines	both	in	
the	presence	and	absence	of	IFN-γ,	however	mRNA	levels	of	PD-L1	increased	steadily	
over	the	course	of	treatment.	This	group	also	found	that	once	cells	developed	resistance	
to	BRAF	inhibition,	PD-L1	levels	increased93.	A	study	by	Atef	and	colleagues	(2014)	
showed	that	Tram	treatment	decreased	PD-L1	levels,	however,	induction	with	IFN-γ	had	
the	potential	to	reverse	this	effect97.	Jiang	et	al	(2013)	also	confirmed	down-regulated	
PD-L1	expression	in	human	melanoma	cells	through	Tram	treatment.	Jiang’s	findings	
also	complimented	that	of	Liu	with	the	decreases	in	PD-L1	expression	combined	with	
increases	in	apoptotic	markers47.	In	a	conflicting	study,	Loi	and	colleagues	(2015)	found	
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increasing	surface	PD-L1	levels	with	Sel	and	Tram	treated	mouse	breast	tumor	lines8	and	
Hu-Lieskovan	et	al	(2015)	also	found	increases	in	PD-L1	expression	in	a	mouse	
melanoma	model	after	Tram	treatment94.		
	
4.6	How	Our	Findings	Compare	to	Literature	
Through	the	course	of	this	research,	our	findings	are	synonymous	with	some	
literature	regarding	the	MEKi-mediated	effects	of	HLA	and	PD-L1	expression,	but	there	
are	some	conflicting	reports.	The	effects	of	U0126-treatment	on	HLA	class	I	expression	
in	all	cell	lines	is	in	agreement	with	Robertson	and	colleagues	(2006)	report	of	decreased	
expression	in	HeLa	cells,	as	well	with	previous	research	from	the	Drover	laboratory77,92.	
The	increase	of	HLA	class	I	through	treatment	with	Sel	and	Tram	is	in	agreement	with	
the	studies	mentioned	above8,94,98.	Our	results	were	consistent	both	in	the	presence	and	
absence	of	IFN-γ,	which	is	in	agreement	with	several	studies8,98.	However,	this	is	not	in	
agreement	with	Atefi	and	colleagues	(2014)43.			
Our	research	has	shown	repeatedly	that	MEK	inhibition	decreases	both	surface	
expression	and	protein	levels	of	PD-L1.	These	data	are	in	agreement	with	some	in	the	
literature93,97,47,	but	are	in	disagreement	with	others8,94.	It	is	worth	noting	that	the	
concentrations	of	Tram	used	in	the	conflicting	paper	by	Loi	and	colleagues	is	much	
higher	than	what	we	use8,	however	experiments	testing	minor	as	well	as	log	fold	
changes	in	concentrations	did	not	perceptibly	alter	our	findings	(appendices	3,4,	8	&	9).	
Even	at	concentrations	well	beyond	that	of	clinical	relevance,	we	demonstrated	that	
neither	Sel	or	Tram	increased	PD-L1	expression	in	our	TNBC	or	non-TNBC	lines.		
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The	conflicting	studies	regarding	MEK	inhibition	on	PD-L1	expression	could	be	
cell	context	dependent,	including	inhibition-resistant	lines,	species	variations	(human	
lines	or	mouse	lines),	as	well	as	the	cross-talk	present	between	the	MAPK	pathway	and	
others	such	as	PI3K/AKT,	and	although	marketed	as	specific	for	MEK,	these	inhibitors	
could	have	off	target	effects.	Human	breast	tumours	could	also	be	modified	the	tumour	
stage,	genetic	background	as	well	as	the	cell	milieu	in	the	tumour	microenvironment	
64,97,99,100	
	
4.7	Research	Limitations	
	 Despite	careful	attention	to	planning	and	executing	this	study,	we	
recognize	that	there	are	some	limitations	that	make	it	difficult	to	draw	firm	conclusions	
concerning	the	effects	of	MEKi	on	expression	of	HLA	and	PD-L1	in	TNBC.		Our	study	used	
eight	human	cell	lines,	a	relatively	small	number,	thus,	additional	lines		would	have	
increased	the	accuracy	of	our	findings,	especially	as	they	pertain	to	the	TNBC	lines.	In	
that	regard,	it	would	also	have	been	informative	to	increase	the	number	of	other	BCCL,	
such	as	ER+	and	HER2+	cell	lines	to	more	clearly	establish	whether	the	modulating	
effects	of	MEKi	on	HLA	and	PD-L1	were	specific	for	TNBC.	We	also	found	that	siRNA	did	
not	completely	knock	down	ERK	1	and	ERK	2,	as	there	were	small	amounts	of	ERK	
proteins	still	visible	in	the	lanes	containing	samples	treated	with	the	siRNA	(Figure	3.6	
A).	Indeed,	the	knockdowns	with	the	chemical	MEKi	were	more	complete	as	pERK	was	
barely	present	in	most	lines	treated	with	the	various	inhibitors.	Therefore,	it	would	have	
been	more	informative	to	knock	down	MEK	1	and	MEK	2	and	to	include	antibodies	that	
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were	also	specific	for	MEK	1	and	MEK	2.	There	were	also	some	issues	with	the	
antibodies	used	for	Western	blotting,	with	some	showing	non-specific	bands	and	high	
amounts	of	background,	as	well	as	disruptions	due	to	antibodies	that	were	discontinued	
during	the	course	of	our	research.	As	the	clinically	relevant	inhibitors	used	were	
relatively	new	during	the	course	of	this	research,	the	concentrations	suggested	by	the	
manufacturers	changed	multiple	times	depending	on	new	literature	published.	Another	
apparent	limitation	is	the	use	of	only	cell	lines,	but	analyzing	tissues	from	tumour	
biopsies	taken	before	and	after	treatment	with	MEKi,	is	beyond	the	scope	of	this	
Master’s	thesis.	Access	to	a	tumour	bank	and	human	tissue	samples	could	help	show	the	
real-world	relevance	of	our	work	to	human	breast	cancer	patients. 
	
4.8	Future	directions	
Future	directions	for	this	research	should	be	centered	on	understanding	the	
underlying	mechanisms	responsible	for	the	altered	expression	of	HLA-DR,	HLA	class	I	
and	PD-L1	via	MEKi(s).	Once	the	mechanisms	are	elucidated,	a	greater	understanding	of	
tumour	cell/T	cell	interactions	within	the	tumour	environment	can	be	gained	as	well	as	
information	regarding	potential	new	opportunities	for	combination	treatments	between	
pathway	inhibitors	and	other	treatments.		
The	effect	of	MEK	inhibition	on	tumour-infiltrating	T	cells	must	also	be	
addressed;	Previous	studies	have	shown	MEK	inhibitors	to	be	immunosuppressive	in	
vitro101,	however	Liu	and	colleagues	(2015)	found	that	Tram-treated	melanoma	cells	
resulted	in	a	partial/transient	inhibition	in	T	cell	proliferation,	but	when	treated	with	a	
combination	of	Tram	and	anti	PD-1,	TIL	levels	increased98.	Also,	Loi	et	al	(2015)	
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suggested	that	MEK	inhibitors	can	help	recruit	TILs8.	This	shows	that	the	effects	of	MEK	
inhibition	on	immune	cells	is	complex	and	context-dependent93.	
Future	directions	should	also	include	RT-PCR	to	test	whether	transcription	of	PD-
L1	is	affected	by	MEK	inhibition	in	TNBC	cells,	as	this	will	help	to	understand	the	
mechanism(s)	underlying	inhibitor-mediated	decreases.	As	there	exists	discrepancies	in	
MEK-inhibition	on	PD-L1	expression	between	studies	using	in	vivo	versus	in	vitro	
models8,98,	the	use	of	in	vivo	TNBC	models	should	be	assessed	to	determine	is	the	
effects	seen	in	human	lines	can	be	translated	to	animal	models.		
	
4.9	Significance	
	 The	potential	to	modulate	the	expression	of	immune	markers	on	tumour	cells	
could	prove	to	be	therapeutically	beneficial	for	those	with	treatment-limited	cancers,	
such	as	TNBC.	Through	hyperactivation	of	the	MAPK	pathway,	cell	growth	and	
proliferation	go	unchecked,	leading	to	tumour	growth	and	metastasis6,8,74,97.	Included	in	
this	rampant	cellular	proliferation,	immune-escape	mechanisms	are	also	employed	to	
down-regulate	antigen	presenting	markers	such	as	HLA	class	I26.	Through	inhibition	of	
the	MAPK	pathway,	the	ability	to	increase	surface	HLA	class	I	could	aid	in	growth	
inhibition	and	tumour	destruction.	In	addition	to	the	increase	in	antigen	presenting	
markers,	the	decreased	expression	of	inhibitory	molecules	such	as	PD-L1	could	
exaggerate	the	chances	of	tumour	destruction	through	decreased	T	cell	inhibition	and	
activation.		
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	 Selumetinib	is	currently	being	tested	in	20	ongoing	clinical	trials70;		and	
Trametinib	is	already	FDA-approved	in	combination	with	an	AKT	inhibitor	for	the	
treatment	of	melanoma70,86,90,102.	With	our	results	with	Sel	and	Tram	consistently	
increasing	HLA	class	I	and	decreasing	PD-L1	levels	across	multiple	cell	lines,	there	exists	
the	possibility	that	these	drugs	may	also	have	therapeutic	benefits	in	TNBC.		
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Appendix	1:	Flow	cytometric	analysis	showing	treated/untreated	values	of	MDA-
231c10A	cells	treated	with	E2	in	combination	or	absence	of	Selumetinib.		
Cells	were	treated	with	Selumetinib	(15	nM)	with	DMSO	as	a	vehicle	control,	E2	(109M)	
in	combination	with	or	alone	with	ethanol	as	vehicle	control,		for	72	hours	and	then	with	
IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	to	determine	A)	Surface	HLA-DR	(L243)	
expression.	B)	Surface	HLA	class	I	(W6/32)	expression.	C)	Surface	PD-L1	(MIH2)	
expression.	
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Appendix	2:	Flow	cytometric	analysis	showing	treated/over	untreated	values	of	MDA-
231c10A	cells	treated	with	E2	in	combination	or	absence	of	Trametinib.		
Cells	were	treated	with	Trametinib	(2	nM)	with	DMSO	as	a	vehicle	control,	E2	(109M)	in	
combination	with	or	alone	with	ethanol	as	vehicle	control,		for	72	hours	and	then	with	
IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	to	determine	A)	Surface	HLA-DR	(L243)	
expression.	B)	Surface	HLA	class	I	(W6/32)	expression.	C)	Surface	PD-L1	(MIH2)	
expression.	
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Appendix	3:	Flow	cytometric	analysis	of	concentration	experiment	with	MDA-231	c10A	
treated	with	Selumetinib	(15	nM,	25	nM	or	50	nM),	or	DMSO	(vehicle	control),	induced	
with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	for	a	total	incubation	time	of	72	hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	4:	Flow	cytometric	analysis	of	concentration	experiment	with	MDA-231	c10A	
treated	with	Trametinib	(2	nM,	5	nM	or	10	nM),	or	DMSO	(vehicle	control),	induced	with	
IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	for	a	total	incubation	time	of	72	hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	5:	Flow	cytometric	analysis	of	concentration	experiment	with	MDA-231	c10A	
treated	with	PD0325901	(0.5	nM,	1	nM,	or	5	nM),	or	DMSO	(vehicle	control),	induced	
with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	for	a	total	incubation	time	of	72	hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	6:	Flow	cytometric	analysis	of	time	course	experiment	with	MDA-231	c10A	
treated	with	Selumetinib	(15	nM),	or	DMSO	(vehicle	control),	induced	with	IFN-γ	(100	
u/ml)	1hr	after	MEKi	treatment	for	total	incubation	time(s)	of	6,	24,	&	48		hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	7:	Flow	cytometric	analysis	of	time	course	experiment	with	MDA-231	c10A	
treated	with	Trametinib	(2	nM),	or	DMSO	(vehicle	control),	induced	with	IFN-γ	(100	
u/ml)	1hr	after	MEKi	treatment	for	total	incubation	time(s)	of	6,	24,	&	48	hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	8:	Flow	cytometric	analysis	of	log	dosage	experiment	with	Selumetinib-
treated	MDA-231	c10A	cells.	
Cells	were	treated	with	Selumetinib	(15	nM,	1500	nM	or	15000	nM),	or	DMSO	(vehicle	
control)	for	72	hours	and	then	with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	9:	Flow	cytometric	analysis	of	log	dosage	experiment	with	Trametinib-treated	
MDA-231	c10A.	
Cells	were	treated	with	Trametinib	(2	nM,	200	nM	or	2000	nM),	or	DMSO	(vehicle	
control)	for	72	hours	and	then	with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
	
	
